[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5164
1. Konukoglu E, Wells WM, Novellas S, Ayache N, Kikinis R, Black PM, Pohl KM: MONITORING SLOWLY EVOLVING TUMORS. Proc IEEE Int Symp Biomed Imaging; 2008 May;2008:812-815

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MONITORING SLOWLY EVOLVING TUMORS.
  • Change detection is a critical task in the diagnosis of many slowly evolving pathologies.
  • We are specifically interested in meningiomas, which experts often find difficult to monitor as the tumor evolution can be obscured by image artifacts.
  • We test the method on synthetic data with known tumor growth as well as ten clinical data sets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Image Comput Comput Assist Interv. 2007;10(Pt 2):319-26 [18044584.001]
  • [Cites] Comput Med Imaging Graph. 2005 Jan;29(1):21-34 [15710538.001]
  • [Cites] Med Image Anal. 2002 Jun;6(2):163-79 [12045002.001]
  • [Cites] Acad Radiol. 2003 Dec;10(12):1341-8 [14697002.001]
  • [Cites] IEEE Trans Med Imaging. 2005 Oct;24(10):1334-46 [16229419.001]
  • [Cites] Clin Radiol. 2007 Jan;62(1):10-7 [17145258.001]
  • (PMID = 28593030.001).
  • [ISSN] 1945-7928
  • [Journal-full-title] Proceedings. IEEE International Symposium on Biomedical Imaging
  • [ISO-abbreviation] Proc IEEE Int Symp Biomed Imaging
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR013218; United States / NCRR NIH HHS / RR / P41 RR019703; United States / NCRR NIH HHS / RR / U41 RR019703; United States / NIBIB NIH HHS / EB / U54 EB005149
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; follow-up / time series analysis / tumor
  •  go-up   go-down


2. Mikropoulos C, Williams T, Munthali L, Summers J: A rare case of anal tumor: Anal carcinosarcoma. World J Gastrointest Oncol; 2010 Dec 15;2(12):446-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of anal tumor: Anal carcinosarcoma.
  • Sarcomatoid carcinoma is a rare tumor with a poor prognosis, otherwise known as carcinosarcoma.
  • Gastrointestinal origin is very rare and only a limited number of anal carcinosarcomas have been reported in the literature.
  • The aim of this case report was to confirm that by combining treatment modalities we can achieve long disease free intervals.
  • Concomitant chemoradiotherapy led to a good partial response and this was followed by a consolidation surgical endo-anal excision.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2006 Mar 7;12(9):1481-4 [16552827.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Jun;18(6):748-9 [12753163.001]
  • [Cites] Hepatogastroenterology. 2000 Nov-Dec;47(36):1611-4 [11149014.001]
  • [Cites] Turk J Gastroenterol. 2006 Sep;17(3):236-9 [16941264.001]
  • [Cites] Histopathology. 1985 Sep;9(9):987-94 [2415439.001]
  • [Cites] Int Surg. 1979 Jan-Feb;64(1):13-9 [536139.001]
  • [Cites] Pathology. 2006 Jun;38(3):264-7 [16753754.001]
  • [Cites] Singapore Med J. 2008 Oct;49(10):e283-5 [18946600.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Semin Diagn Pathol. 1993 May;10(2):118-27 [8367621.001]
  • (PMID = 21191539.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3011099
  • [Keywords] NOTNLM ; Anal tumour / Carcinosarcoma / Chemoradiotherapy / Endo-anal excision / Spindle cell
  •  go-up   go-down


3. Tanaka S, Ohta T, Fujimoto T, Makino Y, Murakami I: Endoscopic mucosal resection of primary anorectal malignant melanoma: a case report. Acta Med Okayama; 2008 Dec;62(6):421-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic mucosal resection of primary anorectal malignant melanoma: a case report.
  • Anorectal melanoma is a rare malignant tumor with a poor prognosis.
  • An 85-year-old man was referred to our hospital for further examination and treatment of an anal tumor 2 cm in size.
  • Endoscopic ultrasonography revealed that the depth of tumor invasion was confined to the submucosal layer.
  • Endoscopic mucosal resection was performed, and the tumor was diagnosed as a malignant melanoma.
  • The patient was followed without any additional treatment, which was per his wishes.
  • If the depth of tumor invasion is shallow, endoscopic mucosal resection is a useful option among other therapeutic modalities.
  • [MeSH-major] Anal Canal / surgery. Endoscopy / methods. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Reoperation

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122689.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Sgourakis G, Lanitis S, Karaliotas C: Clinical challenges and images in GI. Anal tumor with refractory hypercalcemia. Gastroenterology; 2010 May;138(5):1667, 2025
MedlinePlus Health Information. consumer health - HPV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical challenges and images in GI. Anal tumor with refractory hypercalcemia.
  • [MeSH-major] Alphapapillomavirus / isolation & purification. Anus Diseases / virology. Anus Neoplasms / virology. Carcinoma, Squamous Cell / virology. Condylomata Acuminata / virology. Hypercalcemia / virology. Papillomavirus Infections / virology. Paraneoplastic Syndromes / virology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332041.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


5. Elgin Y, Demirkasimoglu T, Kucukplakci B, Altundag MB, Altundag K, Misirlioglu C, Sanri E, Erkal H, Ugur I, Kara P, Ozgen A, Ozdamar N: Anal tumor diagnosed after the recovery of Fournier gangrene. Dig Dis Sci; 2006 May;51(5):889-90
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal tumor diagnosed after the recovery of Fournier gangrene.
  • [MeSH-major] Adenocarcinoma / complications. Anus Neoplasms / complications. Fournier Gangrene / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642420.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


6. Scarpini C, White V, Muralidhar B, Patterson A, Hickey N, Singh N, Mullerat J, Winslet M, Davies RJ, Phillips ML, Stacey P, Laskey RA, Miller R, Nathan M, Coleman N: Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2855-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins.
  • PURPOSE: Early detection of anal intraepithelial neoplasia (AIN) and anal squamous cell carcinoma (SCC) by screening will improve clinical outcome.
  • Assessment of anal cytology samples using routine Papanicolaou testing suffers from shortcomings in sensitivity and/or specificity, suggesting that screening tests based on biomarkers may be of value.
  • EXPERIMENTAL DESIGN: We undertook an initial immunohistochemical study of 54 anal tissue samples and validated our findings using an independent prospective cohort study of 235 anal cytology samples from 144 subjects.
  • RESULTS: In the progression from normal anal epithelium through AIN to SCC, there was increasing expression of MCM2 and MCM5, including in the superficial epithelial third, the source of the majority of cells collected by anal swab.
  • By immunocytochemistry using a mixture of anti-MCM2 and anti-MCM5 antibodies, immunopositive cells were readily identified in anal cytology samples, even at low magnification.
  • CONCLUSIONS: MCMs are promising biomarkers for improving detection of AIN and SCC in anal cytology samples.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cell Cycle Proteins / metabolism. Nuclear Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Middle Aged. Minichromosome Maintenance Complex Component 2. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843031.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105359875; United Kingdom / Medical Research Council / / MC/ U105359878; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / MCM5 protein, human; 0 / Nuclear Proteins; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


7. Ortholan C, François E, Gérard JP: [Chemoradiotherapy and anal canal cancer]. Bull Cancer; 2005 Dec;92(12):1039-47
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemoradiotherapy and anal canal cancer].
  • [Transliterated title] Chimioradiothérapie des cancers du canal anal.
  • Local control and sphincter preservation are the two challenges of anal canal cancer treatment.
  • These tumors are radio- and chemo-sensitive and treatment moved from surgical approach, with abdominoperineal resection, to definitive radiation therapy with or without concurrent chemotherapy.
  • Indications of chemoradiotherapy are locally advanced tumor T2 > or = 4 cm, T3-4 or N1-3 but the best modalities of combined treatment are still under debate.
  • This article is a review of past randomised trials, phases II and retrospective study on radiochemotherapy of anal canal carcinoma.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396750.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Pyrimidines; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Nadal SR, Horta SH, Calore EE, Manzione CR: [Outcome of treatment of anal squamous cell carcinoma and its precursor in HIV-infected patients]. Rev Assoc Med Bras (1992); 2007 Jul-Aug;53(4):365-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Outcome of treatment of anal squamous cell carcinoma and its precursor in HIV-infected patients].
  • [Transliterated title] Resultados do tratamento do carcinoma espinocelular anal e do seu precursor em doentes HIV-positivos.
  • OBJECTIVE: Incidence of anal squamous cell carcinoma is increasing mainly among HIV-positive patients.
  • Treatment consists of radiotherapy and chemotherapy, sometimes followed by tumor resection.
  • This is a report of cases treated at the "Instituto de Infectologia Emílio Ribas", Sao Paulo, Brazil.
  • Thirty patients had high grade anal intra-epithelial neoplasia (HAIN), treated with local resection, and 15 with anal canal invasive squamous cell carcinoma were first submitted to chemo radiation, while biopsies were obtained during follow-up.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Seropositivity. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Biopsy. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Treatment Failure. Treatment Outcome. Treatment Refusal / statistics & numerical data

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17823743.001).
  • [ISSN] 0104-4230
  • [Journal-full-title] Revista da Associação Médica Brasileira (1992)
  • [ISO-abbreviation] Rev Assoc Med Bras (1992)
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


9. Schweitzer A: [Giant anal tumor. The patient is not bothered by it]. MMW Fortschr Med; 2008 Apr 17;150(16):5
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant anal tumor. The patient is not bothered by it].
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenoma / diagnosis. Anus Neoplasms / diagnosis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Cell Transformation, Neoplastic / pathology. Diagnosis, Differential. Female. Humans. Rectum / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18557104.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Baccouche D, Sriha B, Denguezli M, Belajouza C, Nouira R, Korbi S: [Peri anal tumor]. Ann Dermatol Venereol; 2005 Apr;132(4):375-7
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peri anal tumor].
  • [Transliterated title] Tumeur végétante péri-anale.
  • [MeSH-major] Anus Diseases / pathology. Crohn Disease / pathology

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15886570.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


11. Schwarz JK, Siegel BA, Dehdashti F, Myerson RJ, Fleshman JW, Grigsby PW: Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys; 2008 May 1;71(1):180-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer.
  • PURPOSE: To evaluate the response to therapy for anal carcinoma using post-therapy imaging with positron emission tomography (PET)/computed tomography and F-18 fluorodeoxyglucose (FDG) and to compare the metabolic response with patient outcome.
  • PATIENTS AND METHODS: This was a prospective cohort study of 53 consecutive patients with anal cancer.
  • Persistent abnormal FDG uptake (partial metabolic response) was found in the anal tumor in 9 patients.
  • The 2-year cause-specific survival rate was 94% for patients with a complete vs. 39% for patients with a partial metabolic response in the anal tumor (p = 0.0008).
  • The 2-year progression-free survival rate was 95% for patients with a complete vs. 22% for patients with a partial metabolic response in the anal tumor (p < 0.0001).
  • CONCLUSIONS: A partial metabolic response in the anal tumor as determined by post-therapy FDG-PET is predictive of significantly decreased progression-free and cause-specific survival after chemoradiotherapy for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Radiopharmaceuticals. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17996387.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Saranovic Dj, Krivokapic Z, Masulovic D, Djuric A, Ivanovic A, Dobriserevic B, Markovic Z, Barisic G: Endoanal ultrasonography in establishing the diagnosis of fecal incontinence. Acta Chir Iugosl; 2007;54(3):159-62
Genetic Alliance. consumer health - Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoanal ultrasonography in establishing the diagnosis of fecal incontinence.
  • Local staging of rectal and anal tumor and perianal neoplasm by conventional and sibgle slice CT or by barium enema study is not so valuable.
  • During last decade, endoscopic ultrasound and magnetic resonance imaging have been recognised as methods of choice in establishing diagnosis of rectal, perirectal, anal and perianal diseases.
  • [MeSH-minor] Anal Canal / ultrasonography. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988050.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


13. Freudenberg S, Palma P, Grobholz R, Ngendahayo L, Post S: HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case. Dis Colon Rectum; 2005 Aug;48(8):1656-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case.
  • PURPOSE: This article describes and discusses primary Burkitt's lymphoma of the anus which is an extremely rare site of origin.
  • METHODS AND RESULTS: A 38-year-old HIV+ Rwandan farmer had an 8-cm x 13-cm anal tumor.
  • CONCLUSIONS: Because of the AIDS epidemic and the increase of anal malignant pathologies, anal Burkitt's lymphoma may appear more frequently.
  • [MeSH-major] Anus Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Adult. Colostomy. Fatal Outcome. HIV Seropositivity / diagnosis. Herpesvirus 4, Human / isolation & purification. Humans. Male. Rectum / surgery

  • Genetic Alliance. consumer health - HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034658.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Lobato LF, Stocchi L, da Luz Moreira A, Kalady M, Dietz D, Geisler D, Lavery I, Fazio V: Effect of downstaging without complete pathologic response after neoadjuvant treatment on cancer outcomes for cIII and cII rectal cancers. J Clin Oncol; 2009 May 20;27(15_suppl):4108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with cII vs. cIII stage were statistically comparable regarding demographics, chemoradiation regimen, interval to surgery after neoadjuvant treatment, tumor distance from anal verge, operations performed and follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961176.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Djellali L, Larbaoui B, Boukerche A, Ghazi S, Chaiba I, Meziane N, Yekrou D, Youcef DF: Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint of this phase II trial was pathologic tumor response.
  • Secondary endpoint was sphincter preservation and toxicity Methods: Inclusion criteria: rectal adenocarcinoma <12 cms from anal verge, clinical stage T3-4, adequate renal, hematological and liver function.
  • Tumor location (from anal verge): < 6 cm in 10pts, >6 cm in 5pts.
  • Tumor down-staging was observed in 10pts (66.6%), including 5pts with complete pathological response (33.3%).
  • Main adverse effects (NCI-CTC): diarrhea G3-4: 14.2%, sensitive peripheral neurotoxicity G1: 26.6%, nausea/vomiting G3-4: 11%, Anemia G3-4: 7.1%, neutropenia G3-4: 14.2% Conclusions: Preliminary results show that preoperative concomitant chemoradiotherapy with oxaliplatin and 5FU-folinic acid is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964340.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Larbaoui B: Preoperative concomitant chemoradiotherapy with capecitabine in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15134

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint of this phase II trial was pathologic tumor response.
  • METHODS: Inclusion criteria: rectal adenocarcinoma <12 cms from anal verge, clinical stage T3-4, adequate renal, hematological and liver function.
  • Tumor location (from anal verge): < 6 cm in 8pts, >6 cm in 7pts.
  • Tumor down staging was observed in 9pts (60%), including 5pts with complete pathological response (33.3%).
  • CONCLUSIONS: Preliminary results show that preoperative concomitant chemoradiotherapy with Capecitabine is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960909.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hensel M, Goetzenich A, Hanhoff N, Wolf E, Knechten H, Mosthaf F: Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e22115

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The questionnaire requested information on all malignancies in HIV-positive pts, tumor stage, CDC (Center for Disease Control)-stage of the HIV infection, sex, treatment and clinical course.
  • The majority of pts had advanced HIV-disease (CDC stage C3), but the proportion of pts with stage C3 decreased from 58% in 2000 to 36.8% in 2007.
  • Among the 299 cases (54.2%) of NAD malignomas were 213 solid tumors including 71 anal carcinomas (= 33.5% of all NAD malignancies) and 85 hemoblastoses including 29 Hodgkin lymphomas (= 9.6% of all NAD malignancies).
  • Anal carcinomas and Hodgkin's lymphomas in particular were markedly more prevalent in our HIV-positive cohort compared to published reports of the general population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Lustberg MB, Nuovo J, Thomas JP, Monk PJ 3rd, Kim S, Villalona-Calero M, Bekaii-Saab T: Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study. J Clin Oncol; 2009 May 20;27(15_suppl):2569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study.
  • : 2569 Background: A principal determinant of the therapeutic index with capecitabine-based treatment is the grade of thymidine phosphorylase (TP) activity in malignant tissue.
  • The beneficial interactions of paclitaxel and carboplatin in upregulation of TP promise to make capecitabine more tumor specific and to provide the expected synergy.
  • METHODS: Patients with advanced solid tumors received carboplatin on day 1, paclitaxel on days 1, 8, 15 and capecitabine orally twice a day on days 8-21, every 4 weeks.
  • There were 10 confirmed responses [4 CR (esophagus, stomach, unknown primary and ampullary); 6 PRs (Pancreas (3), unknown primary, anal and esophagus] and stabilization of disease > 3 months in 12 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961879.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Velenik V, Ocvirk J, Oblak I, Anderluh F: Neoadjuvant cetuximab, capecitabine, and radiotherapy (RT) in locally advanced resectable rectal cancer: results of a phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The radiosensitizing effect of cetuximab, an EGFR-targeting monoclonal antibody, may further enhance the tumor response.
  • Tumor regression grades (TRG) were evaluated on surgical specimens according to Dworak.
  • Three pts (8.1%) had T3N0 tumors, 1 pt (2.7%) T2N1, 13 pts (35%) T3N1, 1 pt (2.7%) T2N2, 15 pts (40.5%) T3N2 and 4 pts (11%) T4N2.
  • The median tumor distance from anal verge was 6 (range: 1-11) cm.
  • The total sphincter preservation rate was 75.7%; in 17 pts whose tumors were located ≤5 cm of the anal verge, the rate was 53%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964401.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Dickson MA, Carvajal RD, Shah M, Tse AN, Dials H, Cane LM, Schwartz GK: A phase I clinical trial of FOLFIRI in combination with the pancyclin-dependentkinase (CDK) inhibitor flavopiridol. J Clin Oncol; 2009 May 20;27(15_suppl):e14511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We conducted a phase I trial of FOLFIRI + F every 2 weeks in patients (pts) with advanced solid tumors.
  • Tumor types: colorectal, gastric, HCC, GE junction, small bowel, pancreas, bile duct, breast, bladder, ovarian, sarcoma, melanoma, anal, urethral, thymic, head & neck, unknown primary.
  • 22 pts had stable disease (median 5.9 m; range 1.5-25.7 m).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963517.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Fakih MG, Pendyala L, Egorin MJ, Fetterly G, Espinoza-Delgado I, Ross M, Phelan J, Kramer Z, Yirinec B, Diasio R: A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):4083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors.
  • Pre-clinical studies demonstrate that vorinostat down-regulates intra-tumor TS in a dose-dependent fashion and augments 5-FU antitumor activity in xenograft models.
  • We conducted a phase I clinical trial of an intermittent schedule of QD x 3 vorinostat in combination with a fixed dose of fluorouracil (5-FU) and leucovorin (LV) in patients (pts) with refractory solid tumors.
  • METHODS: Vorinostat was escalated in a standard 3 x 3 design in combination with a fixed dose of 5-FU and LV (simplified de Gramont regimen, sFULV2).
  • 21 pts had colorectal cancer (CRC), 1 had gastric, 1 had esophageal, and 1 had anal cancer.
  • An expanded MTD cohort is accruing to investigate 5-FU-vorinostat PK interaction and intra-tumor TS down-regulation. (This work was supported by a grant from CTEP and the ACS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961640.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Avallone A, Delrio P, Di Gennaro E, Pecori B, Aloi L, Tatangelo F, Petrillo A, Budillon A, Caracò C, Sandomenico C, Comella P: Evaluation of two different schedules of bevacizumab (BEV) with oxaliplatin (OXA), raltitrexed (TOM), levo-folinic acid (LFA), and 5-fluorouracil (5-FU) during preoperative (preop) pelvic RT in high-risk locally advanced rectal cancer (HR-LARC) patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):e14546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14546 Background: OXA, RTX, 5FU, and LFA during preop pelvic RT produced a high rate of complete (TRG1) or subtotal (TRG2) tumor regression in HR-LARC.
  • METHODS: Inclusion criteria were: cT4, cN+, cT3(<5 cm from the anal verge and/or +ve CRM), resectable M1.
  • Changes of circulating endothelial cells (CECs)assessed by flow cytometry in 17 (7 A; 10 B) pts, and glucose metabolism evaluated by FDG-PET in 27 (15 A; 12 B) pts after 1st c of CT were used as surrogate markers of tumor response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Hohenberger P, Oladeji O, Licht T, Dimitrakopoulou-Strauss A, Jakob J, Pink D, Schwarzbach M, Ströbel P, Reichardt P, Wardelmann E: Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):10550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST).
  • : 10550 Background: We assessed the outcome of patients with locally advanced gastrointestinal stromal tumors (GIST) undergoing preoperative therapy with imatinib.
  • METHODS: 36 patients with biopsy proven GIST (23 f, 13 m, median age 58 (27-85) yrs, 31 primary tumors, 5 local recurrences) of the esophagus/EGJ (n=5), stomach (n=17), duodenum (n=2), small bowel (n=3), or rectum (n=9) were treated with imatinib 400mg/d for 6 mos. preop.
  • Average tumor size was 10.5 cm (4-28 cm).
  • According to Consensus two tumors were low risk, 11 intermediate, and 23 were high risk for aggressive behaviour.
  • 33 pts. completed the treatment schedule, two died from unrelated disease, another one had to be operated for tumor rupture.
  • Of the remaining 33, median tumor size shrank to 55 mm.
  • Complete tumor removal was possible in 28 pts without operative mortality, but two pts showed previously undetected peritoneal spread (R2 resection).
  • The extent of resection found 5 of 6 inoperable pts now resectable and in 21/25 pts a less extensive procedure could be performed in comparison to recommendations by previous tumor boards (segmental gastric resection for gastrectomy, avoidance of pancreatectomy, transanal resection instead of colo-anal anastomosis).
  • Substantial tumor shrinkage facilitates radical but conservative surgery and results in organ-preservation in the overwhelming majority of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Mita MM, Tolcher A, Gordon MS, Rosen L, Mita A, Fine G, Choy G, Berk G: A phase Ib dose-escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly refractory solid tumor patients. J Clin Oncol; 2009 May 20;27(15_suppl):e13511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase Ib dose-escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly refractory solid tumor patients.
  • : e13511 Background: MP-470 (MP) is an oral multi-targeted tyrosine kinase inhibitor which inhibits a number of validated tumor targets including c-kit, flt3, and PDGFα.
  • Adults with ECOG PS of 0-2 and malignant disease appropriate for SOC regimens consisting of paclitaxel/carboplatin (PC), carboplatin/etoposide (CE), topotecan, docetaxel, and erlotinib were enrolled.
  • Six PRs (2 neuroendocrine, 2 SCLC, 1 NSCLC, 1 small cell of anal canal) and 3 SDs (≥ 4 cycles) was observed.
  • CONCLUSIONS: MP470 combined with carboplatin-containing regimens may promote tumor regression and may also sensitize/resensitize tumors to the anticancer effects of such agents.
  • An amendment will be issued to collect tumor tissue biopsy at baseline and during treatment to adequately evaluate DNA damage in tumor tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961308.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Sueda K, Ikenaga M, Miyazaki M, Yasui M, Mishima H, Tsujie M, Omiya H, Miyamoto A, Hirao M, Takami K, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2656-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
  • He presented with an anal tumor with bilateral inguinal nodal metastasis and pain in the anus; the tumor was diagnosed as stage IIIb (cA1N2M0).
  • However, CT performed 2 years after the diagnosis showed a recurrence in the hilar and mediastinal lymph node.
  • However, the treatment response was graded as progressive disease, and the treatment was changed from CDDP to mitomycin C (MMC).
  • The patient developed non-hematologic toxicity and died within 3 years of the diagnosis.
  • We report a case of squamous cell carcinoma of the anus with associated HIV infection.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. HIV Seropositivity / complications


26. Delikoukos S, Zacharoulis D, Hatzitheofilou C: Local posterior perianal block for proctologic surgery. Int Surg; 2006 Nov-Dec;91(6):348-51
MedlinePlus Health Information. consumer health - Anal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 72 patients with proctologic disorders consented to operation under LPPB for stapled hemorrhoidectomy, Milligan-Morgan hemorrhoidectomy, subanodermal fistula resection, perianal abscess revision, and anal tumor electrocoagulation.
  • [MeSH-major] Anus Diseases / surgery. Nerve Block
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / innervation. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256435.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


27. Kidd EA, Dehdashti F, Siegel BA, Grigsby PW: Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol; 2010 Jun;95(3):288-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis.
  • PURPOSE: To evaluate anal cancer uptake of F-18 fluorodeoxyglucose (FDG) measured as the maximum standardized uptake value (SUV(max)) by positron emission tomography (PET) and its correlation with prognostic factors.
  • PATIENTS AND METHODS: The study population consisted of 77 patients with stages 0-IIIB anal cancer who underwent pre-treatment FDG-PET.
  • Tumor histology included 65 squamous cell, 11 basaloid, and 1 small cell cancers.
  • SUV(max) and clinical tumor size were not associated (R(2)=0.338).
  • Higher SUV(max) was associated with an increased risk of nodal metastasis at diagnosis (p<0.0001).
  • Higher SUV(max) was associated with worse disease-free survival (p=0.05).
  • Patients with high anal tumor SUV(max) at diagnosis were at an increased risk of persistent or recurrent disease on post-therapy FDG-PET performed less than 4months after completing therapy (p=0.0402).
  • CONCLUSIONS: SUV(max) is a valuable biomarker of anal cancer prognosis, predicting increased risk of lymph node metastasis and worse disease-free survival.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacokinetics. Positron-Emission Tomography. Radiopharmaceuticals / pharmacokinetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20231040.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


28. Hosono S, Ohira M, Maeda K, Muguruma K, Nishihara T, Inoue T, Yashiro M, Hirakawa K: Synchronous adenocarcinomas of the ileum and transverse colon detected by capsule endoscopy: report of a case. Surg Today; 2006;36(7):663-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neither gastrointestinal endoscopy nor computed tomography showed by abnormal findings; however, a capsule endoscopy, performed to detect obscure gastrointestinal bleeding, revealed a tumor in the ileum.
  • When we tried to take biopsies of the ileal tumor by push enteroscopy via the anus, we found another tumor in the transverse colon.
  • On exploration, tumors were identified in the ileum and the transverse colon.
  • [MeSH-major] Adenocarcinoma / pathology. Capsule Endoscopy. Colonic Neoplasms / pathology. Ileal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2005 Feb;61(2):255-61 [15729235.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Scand J Gastroenterol. 2005 Jun;40(6):725-33 [16036534.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] Endoscopy. 2004 Dec;36(12):1060-6 [15578295.001]
  • [Cites] Indiana Med. 1991 Jun;84(6):392-6 [1918906.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Can J Gastroenterol. 2004 Sep;18(9):559-65 [15457295.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2004 Jan;14(1):51-60 [15062380.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Endoscopy. 2004 Jan;36(1):32-41 [14722853.001]
  • [Cites] Gut. 2003 Aug;52(8):1122-6 [12865269.001]
  • [Cites] Int J Epidemiol. 1996 Aug;25(4):722-8 [8921448.001]
  • (PMID = 16794807.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. Baatrup G, Bolstad M, Mortensen JH: Rigid sigmoidoscopy and MRI are not interchangeable in determining the position of rectal cancers. Eur J Surg Oncol; 2009 Nov;35(11):1169-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE:. 1) To analyse for interchangeability of rigid sigmoidoscopy and MRI in determining the distance from anus to tumour, and to determine if anterior/posterior location influences this difference.
  • 2) To analyse the effect of preoperative chemo-radiotherapy on the distance from anus to tumour.
  • RESULTS: The mean distance from the anal verge to the tumour measured by sigmoidoscopy was 82mm and by MRI 61mm (p<0.01).
  • The length of the tumours decreased by 16mm after neoadjuvant treatment, but the distance from tumour to anus increased by only 4mm. CONCLUSION:.
  • 1) MRI and sigmoidoscopy are not interchangeable in determining the distance from anus to tumour simply by correcting for the length of the anal canal.
  • 2) The gain in tumour free distance above the anus induced by neoadjuvant treatment is small.
  • [MeSH-major] Anal Canal / pathology. Magnetic Resonance Imaging / methods. Rectal Neoplasms / pathology. Sigmoidoscopy / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249188.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Divis P, Vlcek P, Capov I, Divisová K, Katolická J, Vanícek J, Kotulánová E: [Evaluation of neoadjuvant chemo-radiotherapy with locally advanced rectal cancer by comparing tumour volume before and after treatment]. Klin Onkol; 2010;23(6):421-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of neoadjuvant chemo-radiotherapy with locally advanced rectal cancer by comparing tumour volume before and after treatment].
  • The aim of the study was to compare the tumour volume reduction before and after the oncological therapy in relation to the change in the CEA value and to the outcome of the histopathological evaluation of response to the treatment.
  • The tumour volume before and after the CRT, percentage reduction in the tumour volume and the relation to the change in the CAE value and the histopathological evaluation were evaluated.
  • RESULTS: The distance between the anus and the tumour was from 3 to 15 centimetres, the average value being 8.1 centimetres.
  • In 5 cases the tumour was not histologically found in the resected specimen.
  • The average tumour volume before CRT was 32.48, range 10.3-88.5, after the CRT the average volume was 20.13, range 4.7-55.1.
  • This relation however has not been proved in the N value change.
  • Only in one-third of the evaluated patients was there a positive change in both T and N classification.
  • No relation between the CEA value and the tumour volume change has been proven.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Neoadjuvant Therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21351419.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


31. Palefsky J: Human papillomavirus and anal neoplasia. Curr HIV/AIDS Rep; 2008 May;5(2):78-85
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus and anal neoplasia.
  • Anal cancer is a rare disease in the general population, but the incidence of anal cancer is higher in certain at-risk groups, such as men who have sex with men (MSM), and immunosuppressed individuals, including those with HIV infection.
  • Among HIV-positive MSM, the incidence of anal cancer may be as high as 10 times greater than current rates of cervical cancer in the general population of women.
  • Anal cancer is associated with human papillomavirus (HPV) infection and may be preceded by high-grade anal intraepithelial neoplasia (HGAIN).
  • HGAIN and anal HPV infection are both highly prevalent in groups at risk for anal cancer.
  • Current issues include determining the effect of antiretroviral therapy on the natural history of HGAIN and the incidence of anal cancer, optimizing diagnostic and therapeutic approaches to HGAIN, and determining the potential for prophylactic HPV vaccines to prevent anal HPV infection and anal cancer in at-risk groups.
  • [MeSH-major] Anus Neoplasms. Carcinoma in Situ. Papillomavirus Infections
  • [MeSH-minor] Anus Diseases / epidemiology. Anus Diseases / virology. Female. HIV Infections / complications. Homosexuality, Male. Humans. Male. Papillomaviridae / isolation & purification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510893.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


32. Tournier-Rangeard L, Peiffert D, Lafond C, Mege A, Metayer Y, Marchesi V, Buchheit I, Uwer L, Conroy T, Kaminsky MC: [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation]. Cancer Radiother; 2007 Jun;11(4):169-77
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation].
  • [Transliterated title] Résultats à long terme et facteurs pronostiques des carcinomes épidermoïdes du canal anal traités par irradiation.
  • PURPOSE: To analyze the prognostic factors of loco regional control (LRC), specific survival (SS) and sphincter conservation (SC) of patients treated by curative and conservative irradiation for an epidermoid cancer of anal canal in our institution.
  • In multivariate analysis, tumor size (>or=40 mm) [RR=2.1], node involvement (RR=2.4), and poor response (<75%) to first course irradiation [RR=1.9], local relapse (RR=4.5) and distant metastases were factors of poor prognosis for SS.
  • Prognosis factors of LCR were tumor size (RR=2.5), response to first course of irradiation (RR=2.9).
  • Prognosis factors of SC were tumor size (RR=1.9) and response to first course of irradiation (RR=2.4).
  • As well as initial tumor extension, response to first course of irradiation was found as prognostic factor on LCR, SS, SC.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400501.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


33. Gavioli M, Losi L, Luppi G, Iacchetta F, Zironi S, Bertolini F, Falchi AM, Bertoni F, Natalini G: Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):370-5
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter.
  • Preoperative therapy can increase the rate of preserving surgery by shrinking the tumor and enhancing its distance from the anal sphincter.
  • The maximal size of the tumor and its distance from the anal sphincter were measured in millimeters before and after preoperative therapy.
  • RESULTS: Of the 90 cases, 82.5% showed tumor downsizing, varying from one-third to two-thirds or more of the original tumor mass.
  • The distance between the tumor and the anal sphincter increased in 60.2% of cases.
  • It was possible in nearly 30% of patients in whom the cancer had reached the anal sphincter before the preoperative therapy.
  • The distal margin was tumor free in these cases.
  • CONCLUSION: The results of our study have shown that in very low rectal cancer, preoperative therapy causes tumor downsizing in >80% of cases and in more than one-half enhances the distance between the tumor and anal sphincter.
  • [MeSH-major] Anal Canal / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Endosonography. Female. Humans. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524570.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


34. Coquard R, Cenni JC, Artru P, Chalabreysse P, Queneau PE, Taieb S, Alessio A, Lledo G: [Definitive treatment of anal canal carcinoma with radiotherapy: adverse impact of a pre-radiation resection. A retrospective study of 57 patients treated with curative intent]. Cancer Radiother; 2009 Dec;13(8):715-20
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Definitive treatment of anal canal carcinoma with radiotherapy: adverse impact of a pre-radiation resection. A retrospective study of 57 patients treated with curative intent].
  • [Transliterated title] Radiothérapie à visée curative du carcinome du canal anal : impact défavorable d'une résection préalable. Etude rétrospective de 57 patients traités en intention curative.
  • PURPOSE: To describe retrospectively the overall survival, the cancer specific survival and the tumor control in an homogeneous series of patients with epidermoid carcinoma of the anal canal treated with definitive radiotherapy; to assess the impact of brachytherapy, chemotherapy and pre-radiotherapy resection on the risk of recurrence.
  • PATIENTS AND METHODS: From 1997 to 2007, 57 patients (pts) presenting with an epidermoid carcinoma of the anal canal (T1: 14, T2: 33, T3-4: 10, N0: 31, N1: 19, N2: 3, N3: 4, M0: 57) were treated with definitive radiotherapy by the same radiation oncologist.
  • Twelve pts had undergone a surgical resection of the tumour before radiotherapy.
  • In multivariate analysis, a pre-radiotherapy resection (p=0.084) had an inverse impact on the tumour control reaching the level of statistical significance and the use of a belly board was of marginal influence (p=0.13).
  • CONCLUSION: Radiotherapy and chemoradiation with cisplatine-based chemotherapy cure a vast majority of patients with epidermoid carcinoma of the anal canal.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / mortality. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Dose Fractionation. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Patient Positioning. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19854092.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. Durães Lde C, Sousa JB: [Anal cancer and sexually transmitted diseases: what is the correlation?]. Rev Col Bras Cir; 2010 Aug;37(4):265-8
MedlinePlus Health Information. consumer health - Sexually Transmitted Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer and sexually transmitted diseases: what is the correlation?].
  • [Transliterated title] Câncer anal e doenças sexualmente transmissíveis: qual a correlação?
  • OBJECTIVE: Anal cancer is a rare tumor, which incidence is influenced by sexual behavior.
  • The purpose of this paper is to verify the correlation between anal cancer and sexually transmitted diseases, such as HPV, HIV, Gonococci infection, Chlamydia infection, syphilis and others.
  • METHODS: All the internments due to anal cancer, HIV, HPV, syphilis, Gonococci infection, Chlamydia infection and other sexually transmitted diseases in public healthy in Brazil were collected at Datasus site between 1998 and 2007.
  • RESULTS: There was a high correlation between anal cancer and HPV admissions (r=0.98, p<0.001).
  • There was negative correlation between anal cancer and Gonococci infection admissions (r=-0.81, p=0.005) and anal cancer and Chlamydia infection (r=-0.74, p=0.014).
  • There was not statistic significant correlation between anal cancer and HIV admissions (r=0.40, p=0.245), between anal cancer and other sexually transmitted diseases (r=0.55, p=0.1), and between anal cancer and syphilis (r=-0.61, p=0.059).
  • CONCLUSION: There was a high positive correlation between anal cancer and HPV admissions in Brazil.
  • There were negative correlations between anal cancer and Gonococci infection and between anal cancer and Chlamydia infection admissions.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / epidemiology. Sexually Transmitted Diseases / complications. Sexually Transmitted Diseases / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21085842.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


36. Rakoto-Ratsimba HN, Rakototiana AF, Rakotosamimanana J, Ranaivozanany A: [Anal adenocarcinoma revealed by a fistula-in-ano. Report of a case]. Ann Chir; 2006 Nov;131(9):564-6
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal adenocarcinoma revealed by a fistula-in-ano. Report of a case].
  • [Transliterated title] Fistule périanale révélatrice d'un adénocarcinome du canal anal. A propos d'une observation.
  • Anal adenocarcinoma revealed by a fistula-in-ano occurs rarely.
  • Symptomatology has no specificity and the diagnosis is often late, in an advanced stage of the sickness.
  • Recurrent or non recurrent fistula-in-ano requires multiple biopsies for pathology analysis in order to screen a related cancer.
  • Tumor dimension, lymph node involvement, histologic grade and treatment modality are independent prognosis factors for survival.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Anus Neoplasms / complications. Anus Neoplasms / diagnosis. Rectal Fistula / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712770.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


37. Rivero Fernández M, García Martos M, Sanz Moya P, Vázquez Romero M, Fernández Amago MT, García Benayas MT, Sánchez-Pobre Bejarano P: [Kaposi's sarcoma with colorectal and anal canal involvement]. Gastroenterol Hepatol; 2010 Aug-Sep;33(7):508-11
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Kaposi's sarcoma with colorectal and anal canal involvement].
  • [Transliterated title] Sarcoma de Kaposi con afectación colorrectal y del canal anal.
  • Kaposi's sarcoma (KS) is a low-grade vascular tumor, with four main variants, one of which is fairly prevalent in HIV-infected patients.
  • The gastrointestinal tract is involved in 40% of patients, but rectal and anal canal involvement is exceptional.
  • We report the case of a 39-year-old HIV-infected man with an unusual presentation of KS with colorectal and anal canal involvement in the absence of cutaneous disease.
  • [MeSH-major] Anus Neoplasms. Colorectal Neoplasms. Neoplasms, Multiple Primary. Sarcoma, Kaposi

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] .
  • (PMID = 20630624.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


38. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Hannoun L, Houry S, Huguet F, Pène F, Parc R, Schlienger M: [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]. Cancer Radiother; 2006 Dec;10(8):572-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
  • [Transliterated title] Carcinomes épidermoïdes du canal anal traités par association concomitante de radiothérapie et de chimiothérapie. Evaluation des résultats fonctionnels.
  • PURPOSE: To evaluate our results after radiation therapy and concomitant chemotherapy in terms of local control, survival and toxicity in patients with anal cancer.
  • RESULTS: At the end of RT with concomitant chemotherapy local tumor clinical complete response rate was 83%.
  • Out of 5 local tumor relapses, 3 were salvaged with APR.
  • The overall local tumor control (LC) rate with or without salvage local treatment were 88%.
  • LC rate with a good anal function scoring (score 0 and 1) was 70%.
  • Among 43 pts who preserved their anus, 98% had a good anal function scoring.
  • The 5-year disease-free survival was 75%.
  • After multivariate analysis, 2 independent predicting factors significantly influenced the disease-free survival: HIV-positive pts (negative vs positive, P=0.032) and clinical tumor response after the first course of radiotherapy (<50% vs >or=50%, P=0.00032).
  • Late severe complication was observed in 3 pts: 2 pts with painful necrosis of the anus requiring colostomy and 1 pt with grade 3 rectal bleeding.
  • The clinical tumor response after the first course of RT and concomitant chemotherapy is probably the most important predictive factor on the disease-free survival.
  • For patients with T3 or T4 lesion and tumor regression <or=50% after the first course of radiation therapy, surgical non conservative treatment should be discussed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Antimetabolites, Antineoplastic / administration & dosage. Brachytherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. HIV Seropositivity. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17110148.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


39. Nadal SR, Calore EE, Manzione CR, Horta SC, Ferreira AF, Almeida LV: Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases. Dis Colon Rectum; 2005 Dec;48(12):2289-93
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases.
  • The analysis of our patients suggests that herpes simplex virus, Types 1 and 2, may cause verrucous lesions simulating neoplasia in patients with AIDS using antiretroviral therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Anus Neoplasms / diagnosis. Herpes Simplex / diagnosis
  • [MeSH-minor] Acyclovir / therapeutic use. Adult. Anal Canal / pathology. Diagnosis, Differential. Female. Humans. Hypertrophy. Immunohistochemistry. Inflammation. Male. Middle Aged. Recurrence


40. Shia J: An update on tumors of the anal canal. Arch Pathol Lab Med; 2010 Nov;134(11):1601-11
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An update on tumors of the anal canal.
  • CONTEXT: The anal canal possesses complex anatomy and histology and gives rise to a variety of tumor types.
  • Challenging issues remain with regard to both the pathologic diagnosis and the clinical management of these tumors.
  • OBJECTIVES: To provide an updated overview of the histogenesis, clinical and pathologic characteristics, diagnostic terminology, and relevant clinical management of the various types of anal canal tumors.
  • DATA SOURCES: Recent literature on clinical and pathologic characteristics of anal canal tumors.
  • CONCLUSIONS: Although most anal canal tumors are of squamous lineage, a complex variety of other tumors also occurs.
  • Recognition of such diverse tumor entities will allow accurate pathologic diagnosis and most optimal clinical management.
  • [MeSH-major] Adenocarcinoma / pathology. Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Melanoma / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21043813.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


41. Abbasakoor F, Boulos PB: Anal intraepithelial neoplasia. Br J Surg; 2005 Mar;92(3):277-90
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia.
  • BACKGROUND: Anal intraepithelial neoplasia (AIN) is believed to be a precursor of anal squamous cell cancer and its incidence is rising in high-risk groups, particularly those infected with the human immunodeficiency virus (HIV).
  • There is no standard management for AIN and this is mainly due to difficulties in both diagnosis and treatment.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms. Carcinoma in Situ. Carcinoma, Squamous Cell
  • [MeSH-minor] Female. HIV Infections / complications. Humans. Immune Tolerance. Male. Papillomavirus Infections / complications. Precancerous Conditions / etiology. Precancerous Conditions / pathology. Precancerous Conditions / surgery. Risk Factors. Tumor Virus Infections / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd.
  • (PMID = 15736144.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 131
  •  go-up   go-down


42. Garrett K, Kalady MF: Anal neoplasms. Surg Clin North Am; 2010 Feb;90(1):147-61, Table of Contents
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal neoplasms.
  • A variety of lesions comprise tumors of the anal canal, with carcinoma in situ and epidermoid cancers being the most common.
  • Less common anal neoplasms include adenocarcinoma, melanoma, gastrointestinal stromal cell tumors, neuroendocrine tumors, and Buschke-Lowenstein tumors.
  • In this article different tumors and management of each, including a brief review of local excision for rectal cancer, are discussed in turn.
  • [MeSH-major] Anus Neoplasms / surgery
  • [MeSH-minor] Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Verrucous / diagnosis. Carcinoma, Verrucous / pathology. Humans. Intestinal Mucosa / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20109639.001).
  • [ISSN] 1558-3171
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


43. Ficari F, Fazi M, Garcea A, Nesi G, Tonelli F: Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula. Suppl Tumori; 2005 May-Jun;4(3):S31
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula.
  • This paper reports six patients with perianal Crohn's disease (CD), who developed anal cancer in chronic anal fistulas.
  • Tumors have been often diagnosed at an advanced stage and had a worse prognosis than cancers arising in the general population as tumor symptoms may mimic symptoms of CD, resulting in delay in diagnosis.
  • Patients with perianal CD should undergo a careful surveillance program for ano-rectal carcinoma, including routine biopsy of any suspected lesion.
  • [MeSH-major] Anus Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / complications
  • [MeSH-minor] Adult. Chronic Disease. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437885.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


44. Poizot-Martin I, Henry M, Benhaim S, Obry-Roguet V, Figarella D, Tamalet C: High level of HPV 16 and 18 DNA load in anal swabs from male and female HIV-1 infected patients. J Clin Virol; 2009 Apr;44(4):314-7
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of HPV 16 and 18 DNA load in anal swabs from male and female HIV-1 infected patients.
  • BACKGROUND: Despite HAART, the prevalence and incidence of anal cancer in HIV-infected individuals have increased.
  • Recently, the relationship between the severity of cervical lesions and oncogenic HPV load was demonstrated; however, few studies have assessed the level and the significance of oncogenic HPV load in patients at risk for anal neoplasia.
  • OBJECTIVES: To assess HPV genotypes and HPV 16/18 DNA load in HIV-1 infected patients at risk for anal neoplasia.
  • STUDY DESIGN: Cross-sectional pilot study from male and female HIV-1 infected individuals at risk for anal neoplasia in an outpatient HIV Clinical Unit of Marseilles university Hospitals.
  • RESULTS: Anal HPV was found in 79% of the patients whereas high-risk (HR) HPV types and infection with multiple HPV types were found in 83% and 61% of the patients, respectively.
  • CONCLUSIONS: Longitudinal studies are needed to evaluate the link between high anal HPV DNA load and progression to anal squamous intraepithelial lesions and anal cancer.
  • [MeSH-major] Anal Canal / virology. DNA, Viral / isolation & purification. HIV Infections / complications. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Papillomavirus Infections / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269245.001).
  • [ISSN] 1873-5967
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


45. O'Connor L, Champagne BJ, Ferguson MA, Orangio GR, Schertzer ME, Armstrong DN: Efficacy of anal fistula plug in closure of Crohn's anorectal fistulas. Dis Colon Rectum; 2006 Oct;49(10):1569-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of anal fistula plug in closure of Crohn's anorectal fistulas.
  • PURPOSE: The efficacy of Surgisis anal fistula plug in closure of Crohn's anorectal fistula was studied.
  • Diagnosis was made by histologic, radiographic, or endoscopic criteria.
  • Each primary opening was occluded by using a Surgisis anal fistula plug.
  • Patients with single fistulas (with 1 primary opening) were most likely to have successful closure using the anal fistula plug.
  • CONCLUSIONS: Closure of Crohn's anorectal fistula tracts using Surgisis anal fistula plug is safe and successful in 80 percent of patients and 83 percent of fistula tracts.
  • [MeSH-major] Crohn Disease / complications. Rectal Fistula / surgery. Surgical Instruments
  • [MeSH-minor] Drainage / instrumentation. Humans. Prospective Studies. Treatment Outcome. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998638.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


46. Vorob'ev GI, Shelygin IuA, Nechushkin MI, Rybakov EG: [Results of surgical treatment of residual and recurrent anal tumors]. Khirurgiia (Mosk); 2008;(8):4-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of surgical treatment of residual and recurrent anal tumors].
  • Radio- or chemotherapy is a modern standard of anal cancer treatment.
  • The study is aimed to evaluate the role of abdominoperineal resection in the treatment of residual and recurrent anal cancer.
  • The complete tumor regression after radiotherapy/radiochemotherapy was achieved in 74(61.1%) of 120 patients with cancer-specific survival rate of 81.7%.
  • Partial tumor regression was registered in 46 of 120 patients.
  • The abdominoperineal resection was performed in 39(84.8%) of patients with the residual tumor.
  • Thus, surgical treatment allowed secondary local tumor control in 76.9% of patients with the 5-year survival rates of 69.0%.
  • The locoregional tumor relapse was diagnosed in 10(13.74%) of 74 patients with the complete tumor regression.
  • The use of abdominoperineal resection allowed the secondary local tumor control and 5 year survival.
  • Thus, abdominoperineal resection remains the method of choice in the treatment of residual and recurrent anal tumors.
  • [MeSH-major] Digestive System Surgical Procedures / methods. Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Endosonography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Russia / epidemiology. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833142.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


47. Hatfield P, Cooper R, Sebag-Montefiore D: Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):419-24
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma.
  • PURPOSE: To report the results of patients with early-stage anal cancer treated using a low-dose, reduced-volume, involved-field chemoradiotherapy protocol.
  • Of the 21 patients, 17 had had lesions that were excised with close (<1 mm) or involved margins, 1 had had microinvasive disease on biopsy, and 3 had had macroscopic tumor <2 cm in diameter (T1).
  • All were considered to have Stage N0 disease radiologically.
  • RESULTS: After a median follow-up of 42 months, only 1 patient (4.7%) had experienced local recurrence and has remained disease free after local excision.
  • CONCLUSION: The results of our study have shown that for patients with anal carcinoma who have residual microscopic or very-small-volume disease, a policy of low-dose, reduced-volume, involved-field chemoradiotherapy produces excellent local control and disease-free survival, with low rates of acute and late toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Dose Fractionation. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919842.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


48. Grabenbauer GG, Kessler H, Matzel KE, Sauer R, Hohenberger W, Schneider IH: Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum; 2005 Sep;48(9):1742-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
  • PURPOSE: This study was designed to assess the long-term results following radiochemotherapy in patients with anal squamous-cell carcinoma and to evaluate the impact of tumor location on response, survival, and colostomy-free survival.
  • PATIENTS AND METHODS: Between 1985 and 2001, a total of 101 patients with anal carcinoma were registered for curative treatment, of whom 77 had involvement of the anal canal alone, 10 cases had extension into the perianal skin, and 14 patients had pure anal margin tumors.
  • Small tumors of the anal margin were not included since they were treated by surgical excision only.
  • Seventy-one patients had no evidence of nodal disease, whereas 30 presented with involved regional nodes.
  • Radiation treatment was directed to the primary tumor region and to the inguinal, perirectal, and internal iliac nodes using a three-field to four-field box technique with 10MV photons up to a total dose of 5040 cGy.
  • Lesions greater than 5 cm received an additional boost by interstitial or external radiation depending on circumferential extension of the residual tumor.
  • RESULTS: Overall survival and colostomy-free survival rates for patients with anal canal cancer were 75 percent and 87 percent at five years, respectively.
  • Patients with anal margin cancer had a less favorable outcome with five-year-overall and colostomy-free survival rates of 54 percent and 69 percent, respectively.
  • After correction for imbalance between anal canal and anal margin tumors, i.e., exclusion of T1 tumors of the anal canal, difference in overall survival remained significant (73 percent vs. 54 percent, P = 0.01).
  • Following multivariate analysis, tumor location (anal canal vs. anal margin, P = 0.02), age (P = 0.003), and dose intensity of chemotherapy (< or =75 percent vs. >75 percent, P = 0.03) remained independent significant factors for overall survival.
  • Initial tumor response at six weeks (P = 0.03) was predictive for colostomy-free survival.
  • CONCLUSIONS: With colostomy-free survival rates around 85 percent, long-term treatment results for anal canal carcinoma have reached a satisfactory level.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991058.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


49. Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD: Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum; 2006 Dec;49(12):1837-41
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
  • INTRODUCTION: Infliximab is a monoclonal antibody against tumor necrosis factor-alpha, which has been shown to be effective in fistulating Crohn's disease.
  • This study was designed to assess the safety and outcome of infliximab therapy combined with surgery for patients with fistulating anal Crohn's disease.
  • METHODS: All patients receiving infliximab for fistulating anal Crohn's disease between 2000 and 2004 were studied.
  • Perianal Crohn's disease activity index before and 8 to 12 weeks after three infusions of infliximab (5 mg/kg) were recorded.
  • Perianal Crohn's disease activity index improved significantly after infliximab infusion (preinfusion: median, 11, range, 8-17; postinfusion: median, 8, range, 5-16; P<0.001).
  • CONCLUSIONS: Infliximab therapy in combination with examination under anesthesia/seton drainage is a safe and effective short-term treatment for fistulating anal Crohn's disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Crohn Disease / therapy. Drainage. Gastrointestinal Agents / therapeutic use. Rectal Fistula / therapy

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041753.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; B72HH48FLU / Infliximab
  •  go-up   go-down


50. Chen SP, Wang XP: Effect of Simotang oral liquid on anal exhaust in patients after abdominal gynecological operation. Chin J Integr Med; 2006 Sep;12(3):221-3
Hazardous Substances Data Bank. GLYCERIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Simotang oral liquid on anal exhaust in patients after abdominal gynecological operation.
  • OBJECTIVE: To study the effect of Simotang oral liquid and glycerin enema on the patients' bowel sound (BS) restoration and anal exhaust after abdominal gynecological operation.
  • METHOD: Ninety patients with benign tumor who had undergone gynecological operation were randomly divided into the Simotang group, treated after operation with Simotang oral liquid; the enema group, treated with glycerin enema, and the control group, non-treated.
  • The restoration time of BS and anal exhaust were observed.
  • RESULTS: Compared with the control group, the restoration time of BS and anus exhaust were both significantly shorter in the Simotang group and the enema group, showing statistical significance (P < 0.05); but the difference between the two treated groups was insignificant (P > 0.05).
  • CONCLUSION: Simotang oral liquid and glycerine enema both could benefit the restoration of anal exhaust and BS after abdominal operation.
  • [MeSH-major] Constipation / drug therapy. Drugs, Chinese Herbal / administration & dosage. Myoma / surgery. Postoperative Complications / drug therapy. Uterine Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Constipation.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005087.001).
  • [ISSN] 1672-0415
  • [Journal-full-title] Chinese journal of integrative medicine
  • [ISO-abbreviation] Chin J Integr Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; PDC6A3C0OX / Glycerol
  •  go-up   go-down


51. Oehler C, Provencher S, Donath D, Bahary JP, Lütolf UM, Ciernik IF: Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature. Radiat Oncol; 2010;5:36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature.
  • BACKGROUND: The split-course schedule of chemo-radiation for anal cancer is controversial.
  • METHODS: Eighty-four patients with invasive anal cancer treated with definitive external beam radiotherapy (RT) with a mandatory split of 12 days (52 patients, Montreal, Canada) or without an intended split (32 patients, Zurich, Switzerland) were reviewed.
  • RESULTS: After a mean follow-up of 40 +/- 27 months, overall survival and local tumor control at 5 years were 57% and 78% (Zurich) compared to 67% and 82% (Montreal), respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1394-400 [17276620.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] Brachytherapy. 2007 Jul-Sep;6(3):218-26 [17681244.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Onkologie. 2008 May;31(5):251-7 [18497514.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):367-75 [18501453.001]
  • [Cites] Cancer J Sci Am. 1996 Jul-Aug;2(4):205-11 [9166533.001]
  • [Cites] Acta Oncol. 2006;45(6):728-35 [16938816.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):354-61 [16168830.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1136-42 [15752894.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):525-32 [9778618.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2329-35 [9191520.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Int J Colorectal Dis. 1992 Dec;7(4):192-6 [1293239.001]
  • [Cites] Ann Surg. 1992 Feb;215(2):150-6 [1546901.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 1991 May 15;67(10):2462-6 [2015547.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):823-31 [12788191.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):114-8 [18472363.001]
  • [Cites] Eur J Surg Oncol. 2008 Aug;34(8):890-4 [18178364.001]
  • [Cites] Radiother Oncol. 2000 Oct;57(1):91-6 [11033193.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • (PMID = 20465811.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2879246
  •  go-up   go-down


52. Borzomati D, Valeri S, Ripetti V, Vincenzi B, Rabitti C, Persichetti P, Valentini V, Trodella L, Caricato M, Coppola R: Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication? Hepatogastroenterology; 2005 May-Jun;52(63):780-4
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication?
  • We report the case of a 47-year-old HIV-negative male affected by a perianal ulcer which occurred after chemoradiation delivered for anal cancer.
  • In spite of a negative biopsy the lesion was highly suspected to be a disease recurrence.
  • Uncontrollable pain and anal stenosis were also present; abdominoperineal resection with a large excision of perianal tissues and reconstruction with bilateral musculocutaneous gracilis flaps was therefore performed.
  • Histology did not confirm tumor recurrence.
  • Thirteen months after surgery, the patient is still alive and free of disease.
  • The introduction of radiotherapy and concomitant chemotherapy has revolutionized the treatment of anal cancer, avoiding demolitive surgery in a large subset of patients.
  • Radionecrosis is an uncommon but potentially devastating event occurring in up to 10% of patients undergoing radiotherapy for anal cancer.
  • It causes clinical (pain, anal stenosis, mucositis and diarrhea) and diagnostic problems (recurrence vs. benign post-attinic lesion).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Neoplasm Recurrence, Local / diagnosis. Perineum / radiation effects. Radiodermatitis / diagnosis. Ulcer / diagnosis
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Surgical Flaps

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966204.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


53. Mistrangelo M, Mobiglia A, Cassoni P, Castellano I, Maass J, Martina MC, Bellò M, Mussa A: [Verrucous carcinoma of the anus or Buschke-Lowenstein tumor of the anus: staging and treatment. Report of 3 cases]. Suppl Tumori; 2005 May-Jun;4(3):S29-30
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Verrucous carcinoma of the anus or Buschke-Lowenstein tumor of the anus: staging and treatment. Report of 3 cases].
  • [Transliterated title] Il carcinoma verrucoso dell'ano o tumore di buschke-lowenstein dell'ano: stadiazione e trattamento presentazione di 3 casi.
  • INTRODUCTION: Giant condyloma acuminatum or Buschke Lowenstein tumor of the anorectal and perianal regions is an uncommon entity that commonly affects genitalia.
  • The hallmark of the disease is the high rate of recurrence (66%) and malignant transformation (56%).
  • MATERIALS AND METHODS: At the Oncological Surgical Department, University of Turin, three patients were diagnosed with a Buschke Lowenstein tumor.
  • In one case we observed a late anal stenosis treated with local dilatations.
  • One patient with a small persistence of the disease was treated with cryotherapy.
  • All inguinal nodes revealed negative to definitive histological exam, that confirmed the diagnosis of Buschke Lowenstein tumor of the primary lesion.
  • CONCLUSIONS: Buschke Lowenstein tumors are rare but extensive lesions difficult to treat.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / surgery. Carcinoma, Verrucous / pathology. Carcinoma, Verrucous / surgery
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Buschke Lowenstein Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437884.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


54. Menkarios C, Azria D, Laliberté B, Moscardo CL, Gourgou S, Lemanski C, Dubois JB, Aillères N, Fenoglietto P: Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol; 2007;2:41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans.
  • BACKGROUND: To compare the dosimetric advantage of three different intensity-modulated radiation therapy (IMRT) plans to a three dimensional (3D) conventional radiation treatment for anal cancer with regards to organs-at-risk (OAR) avoidance, including iliac bone marrow.
  • METHODS: Five patients with T1-3 N0-1 anal cancer and five with T4 and/or N2-3 tumors were selected.
  • Clinical tumor volume (CTV) included tumor, anal canal and inguinal, peri-rectal, and internal/external iliac nodes (plus pre-sacral nodes for T4/N2-3 tumors).
  • CONCLUSION: IMRT is superior to 3D conformal radiation treatment for anal carcinoma with respect to OAR sparing, including bone marrow sparing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2006 Oct;176(4 Pt 1):1415-9 [16952647.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(1):82-6 [16983394.001]
  • [Cites] Radiother Oncol. 2007 Feb;82(2):160-6 [17222931.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1394-400 [17276620.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1153-60 [2599903.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1319-39 [7713791.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1731-6 [8625041.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):575-81 [9261527.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):249-56 [9572617.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):907-16 [11240231.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704 [11395238.001]
  • [Cites] J Urol. 2001 Sep;166(3):876-81 [11490237.001]
  • [Cites] Radiother Oncol. 2001 Dec;61(3):275-80 [11730997.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1388-96 [12459361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):823-31 [12788191.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):516-21 [12957265.001]
  • [Cites] Phys Med Biol. 1961 Jan;5:255-8 [13726497.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1136-42 [15752894.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):274-81 [16111597.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):354-61 [16168830.001]
  • (PMID = 18005443.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2204019
  •  go-up   go-down


55. Sato H, Maeda K, Koide Y, Matsuoka H, Noro T, Honda K, Shiota M, Endo T, Ozeki S, Fukuda M: [Four cases of anal squamous cell carcinoma treated by chemoradiotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2647-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Four cases of anal squamous cell carcinoma treated by chemoradiotherapy].
  • We reviewed clinical records of 4 cases with squamous cell carcinoma in anus to evaluate the clinical effectiveness of the chemoradiotherapy.
  • The radiation therapy consisted of 40 Gy was delivered to pelvis and bilateral inguinal lesion, and perianal booster dose of 20 Gy, in fractions of 2.0 Gy per day, was given five days a week.
  • Three patients had T2 tumor, and one patient had T1 tumor.
  • All patients had complete response in the anal lesion after chemoradiotherapy.
  • No patients had any sign of recurrence in anal lesion.
  • Chemoradiotherapy was expected to be a safe and effective treatment to improve prognosis for anal squamous carcinoma.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224667.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


56. Kreuter A, Jesse M, Potthoff A, Brockmeyer NH, Gambichler T, Stücker M, Bechara FG, Pfister H, Wieland U: Expression of proliferative biomarkers in anal intraepithelial neoplasia of HIV-positive men. J Am Acad Dermatol; 2010 Sep;63(3):490-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of proliferative biomarkers in anal intraepithelial neoplasia of HIV-positive men.
  • BACKGROUND: Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated precursor lesion of anal carcinoma, is highly prevalent among HIV-infected individuals, especially in men having sex with men (MSM).
  • Early diagnosis and treatment of AIN might prevent development of anal cancer.
  • OBJECTIVES: We aimed to evaluate the expression of 8 promising proliferative biomarkers in anal dysplasia and to compare the efficacy of these markers in diagnosing high-grade AIN.
  • METHODS: Immunohistochemical analysis of minichromosome maintenance proteins (MCM3, MCM4, MCM6, and MCM7), p21, Ki-67, p16, and proliferating cell nuclear antigen (PCNA) was performed in a total of 49 specimens of normal anal mucosa and high- and low-grade anal dysplasia.
  • Sensitivity and specificity of PCNA and p21 for a high-grade AIN diagnosis were lower.
  • [MeSH-major] Anus Neoplasms / pathology. Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. HIV Infections / diagnosis. Proliferating Cell Nuclear Antigen / metabolism
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antiretroviral Therapy, Highly Active / methods. Biopsy, Needle. DNA, Viral / analysis. HIV Seropositivity. Homosexuality, Male. Humans. Immunohistochemistry. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male. Middle Aged. Neoplasm Staging. Papillomavirus Infections / complications. Papillomavirus Infections / diagnosis. Polymerase Chain Reaction / methods. Precancerous Conditions / pathology. Reference Values. Risk Assessment. Sensitivity and Specificity. Viral Load. Young Adult

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20006407.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Viral; 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


57. Raffetto N, Monaco A, Banelli E: Radiotherapy and chemotherapy in the conservative treatment of anal canal carcinoma. Anticancer Res; 2008 Mar-Apr;28(2B):1335-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and chemotherapy in the conservative treatment of anal canal carcinoma.
  • AIM: To evaluate the feasibility of conformal radiotherapy and concurrent chemotherapy in patients with anal canal carcinoma.
  • PATIENTS AND METHODS: Between 1990 and 2006, 83 patients affected by anal canal carcinoma were treated at the Radiotherapy Department of "La Sapienza" University of Rome.
  • In all patients, a daily dose of 1.8 Gy, five times per week, was given for a total dose of 45 Gy for the whole pelvis (CTV1) and of 55-60 Gy for the tumor bed (CTV2).
  • Local tumor relapse was observed in 13 patients (15.6%).
  • CONCLUSION: This analysis suggests that the treatment scheme employed was effective for anal sphincter preservation and local control.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy
  • [MeSH-minor] Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Staging. Radiotherapy, Conformal / adverse effects. Radiotherapy, Conformal / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505075.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


58. Rowe NM, Meisher IE, Sheka KP, Bopaiah V: Leiomyosarcoma of the anal canal: a case report. Int J Surg; 2007 Oct;5(5):345-50
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of the anal canal: a case report.
  • BACKGROUND: Leiomyosarcoma (LMS) of the colon, rectum, and anus comprise less than 0.1% of all rectal malignancies with isolated leiomyosarcomas of the anal canal representing only eight reported cases.
  • CASE REPORT: An 80-year-old male presented with a complaint of bright red blood per rectum, constipation, and a subjective history of a rectal mass diagnosed 3 years prior.
  • Pertinent findings on physical exam included a hard, non-mobile mass in the anus which biopsy showed to be a LMS.
  • At the time of operation the perianal mass extended from the external sphincters into the anal canal.
  • CONCLUSION: Isolated LMS of the anus is an extremely rare finding with only eight previous reports in the world literature.
  • LMS is an aggressive tumor with a high local recurrence rate as well as significant hematogenous spread.
  • [MeSH-major] Anus Neoplasms / surgery. Leiomyosarcoma / surgery. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561465.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Baik SH, Kim NK, Lee KY, Sohn SK, Cho CH: Analysis of anal sphincter preservation rate according to tumor level and neoadjuvant chemoradiotherapy in rectal cancer patients. J Gastrointest Surg; 2008 Jan;12(1):176-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of anal sphincter preservation rate according to tumor level and neoadjuvant chemoradiotherapy in rectal cancer patients.
  • The anal sphincter preservation rate (ASPR) according to tumor level and neoadjuvant chemoradiotherpy (CRT) has not been fully evaluated.
  • Therefore, the aim of this study was to evaluate the correlation between the tumor level, neoadjuvant CRT, and the ASPR in rectal cancer patients.
  • We studied 544 patients (tumor level, 0-6 cm) who underwent curative resection for rectal cancer between 1991 and 2005.
  • Patients were divided six into groups according to tumor level over 1-cm intervals, and the ASPR was evaluated in patients with and without neoadjuvant CRT according to tumor level.
  • In an analysis according to tumor level, the ASPR was 0.0 vs 0.0% in <or=1 cm, 0.0 vs 2.1% in 1<or=2 cm (P=0.589), 11.8 vs 16.8% in 2<or=3 cm (P=0.599), 55.6 vs 20.2% in 3<or=4 cm (P=0.001), 57.7 vs 45.9% in 4<or=5 cm (P=0.227), and 66.7 vs 69.5% in 5<or=6 cm (P=0.827).
  • Neoadjuvant CRT did not increase the ASPR in tumor level within <or=6 cm.
  • However, for the tumor level (3<or=4 cm), neoadjuvant CRT significantly increased the ASPR.
  • [MeSH-major] Adenocarcinoma / therapy. Anal Canal / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colectomy / methods. Neoadjuvant Therapy / methods. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694418.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


60. Lisovsky M, Patel K, Cymes K, Chase D, Bhuiya T, Morgenstern N: Immunophenotypic characterization of anal gland carcinoma: loss of p63 and cytokeratin 5/6. Arch Pathol Lab Med; 2007 Aug;131(8):1304-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic characterization of anal gland carcinoma: loss of p63 and cytokeratin 5/6.
  • Anal gland carcinoma (AGC) is a rare perianal invasive cancer composed of tubular glands lined by cuboidal epithelium.
  • The clinical features and histogenesis of AGC are not well understood and its origin from anal glands is often difficult to prove.
  • Little is known about immunophenotypic features of AGC that could be useful in establishing the diagnosis.
  • This study evaluated the immunohistochemical profile of 2 cases of AGC in comparison to anal glands from 11 hemorrhoidectomy specimens.
  • In biopsies from this case, the neoplastic anal glands had a tubular pattern, whereas most glands in the resection specimen exhibited mucinous features.
  • Normal anal glands showed immunoreactivity for myoepithelial and basal cell markers CK5/6 and p63 in basal and parabasal cell layers and for CK7 in superficial cell layers.
  • Anal gland carcinoma shares negativity for CDX2 and CK7+/CK20- profile with normal anal glands.
  • No evidence of myoepithelial cells was found in normal or malignant anal glands.
  • These data may be useful in establishing the diagnosis of AGC.
  • [MeSH-major] Adenocarcinoma / pathology. Anus Neoplasms / pathology. Biomarkers, Tumor / metabolism. Keratin-5 / metabolism. Keratin-6 / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Anal Canal / metabolism. Anal Canal / pathology. Fluorescent Antibody Technique, Indirect. Hemorrhoids / pathology. Hemorrhoids / surgery. Humans. Immunoenzyme Techniques. Immunophenotyping. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Pathol Lab Med. 2008 Oct;132(10):1547-8 [18834205.001]
  • (PMID = 17683193.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Keratin-6; 0 / Membrane Proteins
  •  go-up   go-down


61. Das P, Crane CH, Ajani JA: Current treatment for localized anal carcinoma. Curr Opin Oncol; 2007 Jul;19(4):396-400
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment for localized anal carcinoma.
  • PURPOSE OF REVIEW: Chemoradiation represents the standard of care for most patients with localized squamous cell carcinoma of the anal canal.
  • This article reviews randomized trials and recent studies on chemoradiation for anal cancer.
  • Recent studies have started to evaluate intensity modulated radiation therapy for anal cancer, in an effort to reduce acute and long-term toxicity from radiotherapy.
  • SUMMARY: The role of cisplatin in anal cancer is not completely clear, although an ongoing randomized trial (Anal Cancer Trial II) may help clarify the role of cisplatin.
  • Studies on tumor biology and patient genetics are warranted to identify patients that are most likely to benefit from newer locoregional and systemic therapies.
  • Intensity modulated radiation therapy appears to be a promising approach for reducing treatment-related toxicity in anal cancer patients.
  • The Radiation Therapy Oncology Group (RTOG) is conducting a phase II trial evaluating the multi-institutional feasibility of intensity modulated radiation therapy for anal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Radiation-Sensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545807.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 21
  •  go-up   go-down


62. Bernard JE, Butler MO, Sandweiss L, Weidner N: Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization. Appl Immunohistochem Mol Morphol; 2008 May;16(3):215-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization.
  • Accurate diagnosis and grading of anal intraepithelial neoplasia (AIN) can be problematic, especially in separating AIN from anal transitional-zone epithelium.
  • To investigate if p16 would help in more accurately diagnosing and grading AIN, particularly when attempting to distinguish benign transitional-zone epithelium from high-grade AIN, we separately assessed these stains in a blinded manner on a large number of consecutive anal biopsies and anal tissues and correlated the findings with the diagnosis and grade of AIN.
  • One hundred thirty-three consecutive anal tissue specimens, from 128 patients were studied.
  • One hundred and eight were anal biopsies and 25 were hemorrhoidectomy specimens.
  • We conclude that the correlation between AIN and p16 and HPV is strong enough to be quite useful in distinguishing true AIN from benign mimics, such as benign transitional-zone epithelium.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301250.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA Probes, HPV
  •  go-up   go-down


63. Seya T, Tanaka N, Shinji S, Yokoi K, Oguro T, Oaki Y, Ishiwata T, Naito Z, Tajiri T: Squamous cell carcinoma arising from recurrent anal fistula. J Nippon Med Sch; 2007 Aug;74(4):319-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma arising from recurrent anal fistula.
  • Here, we report on a patient with squamous cell carcinoma (SCC) arising from recurrent anal fistula.
  • Six months before her admission to our hospital, anal pain developed.
  • She had no history of inflammatory bowel disease.
  • Physical examination revealed three external fistulous openings at the two o'clock position, 2 cm from the anal verge.
  • Microscopic examination showed SCC arising from the anal fistula, which was accompanied by vessel invasion.
  • The tumor was observed to be continuous from the external opening but was not exposed to the internal opening of the rectal mucosa.
  • Urological examination revealed urinary bladder cancer, and transurethral resection of the bladder tumor was performed.
  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded surgical tumor specimens for p53, MLH1, and MSH2 was performed.
  • The tumor specimens showed no MLH1 expression but did show normal MSH2 expression. p53 was not expressed.
  • Five microsatellite loci were examined using the tumor specimens to detect MSI, namely two loci with mononucleotide runs (i.e., BAT25 and BAT26) and three loci with dinucleotide repeats (i.e., APC, Mfd15, and D2S123).
  • The tumor specimens showed alternations in the repeated sequences of two loci (i.e., BAT26 and D2S123).
  • As a result, the tumor was classified as MSI-H (high) according to the Bethesda criteria.
  • Our patient had MSI and one of the smallest reported SCCs arising from recurrent anal fistulae.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma, Squamous Cell / etiology. Rectal Fistula / complications
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Female. Humans. Microsatellite Instability. Middle Aged. Neoplasms, Second Primary / pathology. Recurrence. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878704.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


64. Doniec JM, Schniewind B, Kovács G, Kahlke V, Loehnert M, Kremer B: Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy. Surg Endosc; 2006 Apr;20(4):673-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy.
  • BACKGROUND: The most appropriate therapy for anal cancer is external beam radiotherapy (EBRT) combined with chemotherapy (CTX).
  • We report on our experience of combined modality therapy of anal cancer and transrectal ultrasound (TRUS)-guided high-dose rate (HDR) afterloading therapy, referring to results of a study published in 1998 by the coauthors.
  • METHODS: From 1993 to 2001, 50 patients with anal cancer were treated.
  • RESULTS: In five patients (10%), tumor recurrence occurred or the tumor did not respond to therapy, and four (8%) developed distant lymph nodes or organ metastases.
  • Specific disease-related 5-year survival was 82%.
  • CONCLUSIONS: TRUS-guided brachytherapy permits excellent local tumor control and results in minimal treatment-related morbidity.
  • Consequently, TRUS-guided brachytherapy may be a useful addition to current combined modality treatment regimens for anal cancer.
  • [MeSH-major] Anus Neoplasms / diagnostic imaging. Anus Neoplasms / radiotherapy. Brachytherapy. Endosonography
  • [MeSH-minor] Aged. Combined Modality Therapy. Digestive System Surgical Procedures / adverse effects. Fecal Incontinence / epidemiology. Fecal Incontinence / etiology. Female. Humans. Incidence. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / surgery. Retreatment. Salvage Therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Cancer. 1983 Apr 1;51(7):1291-6 [6825051.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):441-50 [9559628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):575-81 [9486607.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1569-79 [8156483.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):59-66 [8365944.001]
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):763-6 [6499614.001]
  • [Cites] Cancer. 1983 May 15;51(10):1830-7 [6831349.001]
  • [Cites] Radiother Oncol. 1996 Nov;41(2):131-4 [9004355.001]
  • [Cites] Cancer. 1981 Jul 15;48(2):411-5 [7237411.001]
  • [Cites] Dis Colon Rectum. 1998 Feb;41(2):169-76 [9556240.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Cancer Radiother. 1999 Nov-Dec;3(6):461-7 [10630158.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):778-82 [7172946.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1226-33 [10189126.001]
  • [Cites] Dis Colon Rectum. 1991 Jun;34(6):482-6 [1903692.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):313-24 [9069302.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1736-40 [8448738.001]
  • (PMID = 16432657.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


65. Kauh J, Koshy M, Gunthel C, Joyner MM, Landry J, Thomas CR Jr: Management of anal cancer in the HIV-positive population. Oncology (Williston Park); 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal cancer in the HIV-positive population.
  • Squamous cell anal cancer remains an uncommon entity; however, the incidence appears to be increasing in at-risk populations, especially those infected with human papillomavirus (HPV) and human immunodeficiency virus (HIV).
  • Given the ability to cure this cancer using synchronous chemoradiotherapy, management practices of this disease are critical.
  • This article considers treatment strategies for HIV-positive patients with anal cancer, including the impact on chemoradiation-induced toxicities and the role of highly active antiretroviral therapy in the treatment of this patient population.
  • Additional changes to the chemotherapy dosing, such as giving 5-FU continuously and decreasing mitomycin dose, are evaluated and considered in relation to radiation field sizes in an effort to reduce toxicity, maintain local tumor control, and limit need for colostomy.
  • The impact of the immune system in patients with HIV and squamous cell carcinoma of the anus and the associated response to therapy remains unknown.
  • Continued studies and phase III trials will be needed to test new treatment strategies in HIV-infected patients with squamous cell cancer of the anus to determine which treatment protocols provide the greatest benefits.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / epidemiology. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. HIV Infections / epidemiology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / methods. Combined Modality Therapy / methods. Comorbidity. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome


66. Wiley DJ, Huh J, Rao JY, Chang C, Goetz M, Poulter M, Masongsong E, Chang CI, Bernard HU: Methylation of human papillomavirus genomes in cells of anal epithelia of HIV-infected men. J Acquir Immune Defic Syndr; 2005 Jun 1;39(2):143-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of human papillomavirus genomes in cells of anal epithelia of HIV-infected men.
  • Intra-anal malignancies disproportionately affect individuals who engage in anal intercourse because of infection with human papillomaviruses (HPVs), with an increased risk attributed to infection with HIV because of a declining immunity against HPvs. Long-term persistence of HPVs suggests yet other mechanisms that determine the clinical outcome, however.
  • Because methylation of HPV DNA represses oncogene expression in cervical samples, we investigated whether this mechanism also occurs in HIV-positive men and studied the methylation of CpG dinucleotides overlapping with the HPV-16 enhancer and promoter in 16 anal samples.
  • In low-grade anal intraepithelial neoplasia (AIN), methylation was high in CpGs overlapping the viral enhancer but rare in promoter positions, whereas methylation was high in promoter regions in high-grade AIN, especially in samples with a high load of viral genomes.
  • We also detected de novo methylation at methylated (me) CpA, meCpT, and meCpC dinucleotides.
  • Our study expands the observation and mapping of HPV DNA methylation to anal infections and the HIV-positive patient population.
  • DNA methylation, taken together with virus load, may be useful to diagnose the emergence of a population of tumor cells.
  • [MeSH-minor] Anal Canal / virology. Base Sequence. Biopsy. DNA Primers. DNA, Viral / genetics. DNA, Viral / isolation & purification. Dinucleoside Phosphates / analysis. Enhancer Elements, Genetic. Homosexuality, Male. Humans. Male. Polymerase Chain Reaction. Virus Latency. Virus Replication

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905729.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-91964; United States / NCI NIH HHS / CA / R01 CA-91964
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Viral; 0 / Dinucleoside Phosphates; 2382-65-2 / cytidylyl-3'-5'-guanosine
  •  go-up   go-down


67. Day E, Betler J, Parda D, Reitz B, Kirichenko A, Mohammadi S, Miften M: A region growing method for tumor volume segmentation on PET images for rectal and anal cancer patients. Med Phys; 2009 Oct;36(10):4349-58
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A region growing method for tumor volume segmentation on PET images for rectal and anal cancer patients.
  • The application of automated segmentation methods for tumor delineation on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) images presents an opportunity to reduce the interobserver variability in radiotherapy (RT) treatment planning.
  • In this work, three segmentation methods were evaluated and compared for rectal and anal cancer patients: (i) Percentage of the maximum standardized uptake value (SUV% max), (ii) fixed SUV cutoff of 2.5 (SUV2.5), and (iii) mathematical technique based on a confidence connected region growing (CCRG) method.
  • The CCRG method is an iterative scheme that relies on the use of statistics from a specified region in the tumor.
  • Results show that the CCRG technique can be used in the segmentation of tumor volumes on FDG-PET images, thus providing treatment planners with a clinically viable starting point for tumor delineation and minimizing the interobserver variability in radiotherapy planning.
  • [MeSH-major] Algorithms. Anus Neoplasms / diagnostic imaging. Fluorodeoxyglucose F18. Image Interpretation, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Positron-Emission Tomography / methods. Rectal Neoplasms / diagnostic imaging

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19928065.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


68. Lê LH, Chetty R, Moore MJ: Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol; 2005 Jul;124(1):20-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor expression in anal canal carcinoma.
  • Most anal canal carcinomas (ACCs) are squamous cell carcinomas (SCCs).
  • SCCs in other tumor sites strongly express epidermal growth factor receptors (EGFRs), the inhibition of which might result in favorable changes in tumor growth.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / metabolism. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Receptor, Epidermal Growth Factor / biosynthesis

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923158.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


69. Kiran RP, Pokala N, Rottoli M, Fazio VW: Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades. Am Surg; 2009 Feb;75(2):163-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades.
  • Chemoradiotherapy is the standard treatment for anal cancer.
  • From a prospective population-based database on radiation and surgical therapy, we compare outcomes for patients with anal cancer undergoing rectal resection after radiation with patients undergoing radiation alone.
  • Patients undergoing surgical resection of the rectum after initial radiation (SRT) for squamous cell carcinoma of the anus, anal canal, cloacogenic zone, and overlapping lesions of the rectum and anal canal from 1983 to 2002 were identified from the Surveillance, Epidemiology and End Results database.
  • Patient and tumor characteristics of SRT were compared with those of patients who underwent radiation alone (RT).
  • RT and SRT had similar median age, gender, and grade of tumor.
  • SRT had more patients with regional stage of disease (66.7 vs 42.4%, P = 0.001).
  • The presence of regional disease appears to be associated with surgical resection after radiotherapy.
  • [MeSH-major] Anus Neoplasms / mortality. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280811.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C: Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA; 2008 Apr 23;299(16):1914-21
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
  • CONTEXT: Chemoradiation as definitive therapy is the preferred primary therapy for patients with anal canal carcinoma; however, the 5-year disease-free survival rate from concurrent fluorouracil/mitomycin and radiation is only approximately 65%.
  • OBJECTIVE: To compare the efficacy of cisplatin-based (experimental) therapy vs mitomycin-based (standard) therapy in treatment of anal canal carcinoma.
  • DESIGN, SETTING, AND PARTICIPANTS: US Gastrointestinal Intergroup trial RTOG 98-11, a multicenter, phase 3, randomized controlled trial comparing treatment with fluorouracil plus mitomycin and radiotherapy vs treatment with fluorouracil plus cisplatin and radiotherapy in 682 patients with anal canal carcinoma enrolled between October 31, 1998, and June 27, 2005.
  • Stratifications included sex, clinical nodal status, and tumor diameter.
  • MAIN OUTCOME MEASURES: The primary end point was 5-year disease-free survival; secondary end points were overall survival and time to relapse.
  • Median age was 55 years, 69% were women, 27% had a tumor diameter greater than 5 cm, and 26% had clinically positive nodes.
  • The 5-year disease-free survival rate was 60% (95% confidence interval [CI], 53%-67%) in the mitomycin-based group and 54% (95% CI, 46%-60%) in the cisplatin-based group (P = .17).
  • CONCLUSIONS: In this population of patients with anal canal carcinoma, cisplatin-based therapy failed to improve disease-free-survival compared with mitomycin-based therapy, but cisplatin-based therapy resulted in a significantly worse colostomy rate.
  • These findings do not support the use of cisplatin in place of mitomycin in combination with fluorouracil and radiotherapy in the treatment of anal canal carcinoma.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Gastroenterol Hepatol. 2009 Jan;6(1):16-7 [19047998.001]
  • [CommentIn] JAMA. 2008 Sep 24;300(12):1410-1; author reply 1411 [18812528.001]
  • (PMID = 18430910.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00003596
  • [Grant] United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U10 CA37422
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


71. Tokar M, Bobilev D, Zalmanov S, Geffen DB, Walfisch S: Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature. Onkologie; 2006 Feb;29(1-2):30-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature.
  • BACKGROUND: We report on a patient with squamous cell anal carcinoma and liver metastases, who underwent multimodal treatment for cure, consisting of repeated partial hepatectomy in combination with chemoradiotherapy.
  • PATIENTS AND METHODS: A 54-year-old woman presented with squamous cell anal carcinoma and liver metastases.
  • She was treated with a combination of chemoradiotherapy for the primary tumor and then underwent surgery for liver metastases.
  • 2 and 5 years after presentation, the patient underwent repeated partial hepatectomies for recurrent liver disease.
  • At present, 5 months after completing therapy and 71 months after the initial diagnosis, she is in good health with no evidence of disease.
  • RESULTS: Repeated partial hepatectomy led to prolonged survival in a patient with squamous cell anal carcinoma metastatic to the liver.
  • CONCLUSIONS: This is the first report of aggressive partial hepatectomy for recurrent liver metastases resulting from anal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2006 Feb;29(1-2):5-6 [16514247.001]
  • (PMID = 16514253.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 19
  •  go-up   go-down


72. Owens SR, Greenson JK: Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas. Am J Surg Pathol; 2007 Feb;31(2):285-90
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas.
  • Anal canal carcinomas account for between 1% and 2% of all gastrointestinal carcinomas in the United States.
  • By far, the most common carcinoma in this site is squamous cell carcinoma, but the differential diagnosis typically includes poorly differentiated adenocarcinoma and well-differentiated neuroendocrine carcinoma or carcinoid tumor.
  • However, accurate diagnosis is imperative, because the treatment differs between squamous carcinoma (chemoradiation) and the other types of carcinoma (surgical therapy).
  • Therefore, we undertook to ascertain its usefulness in the diagnosis of squamous carcinomas in the anal canal.
  • We retrieved 24 anal squamous carcinomas, 68 colorectal adenocarcinomas (including a tissue microarray), and 32 colorectal neuroendocrine carcinomas from the archives at the University of Michigan, and immunostained them for the p63 antigen.
  • It also stained the dysplastic epithelial cells in adjacent areas of anal intraepithelial neoplasia.
  • We report that the p63 immunostain is a highly specific and useful tool in the diagnosis of carcinomas of the anal canal.
  • [MeSH-major] Anal Canal / metabolism. Anus Neoplasms / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. DNA-Binding Proteins / metabolism. Immunoenzyme Techniques / methods. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Carcinoid Tumor / diagnosis. Carcinoid Tumor / metabolism. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / metabolism. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Diagnosis, Differential. Humans. Predictive Value of Tests. Tissue Array Analysis. Transcription Factors

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255774.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


73. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G: Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res; 2006 Jun 1;12(11 Pt 1):3355-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma.
  • PURPOSE: Tumor-infiltrating lymphocytes (TIL) are a possible prognostic factor in solid tumors.
  • We have evaluated the effect of T-cell subsets on survival in patients with anal squamous cell carcinoma following radiochemotherapy.
  • METHODS: Biopsy specimens from 38 patients with anal carcinomas were evaluated using tissue microarrays and immunohistochemistry for the presence of tumor-infiltrating immune cells using CD3, CD4, CD8, and CD68 antibodies.
  • Prognostic effect of TIL subsets was evaluated by the log-rank test comparing no evidence of disease survival for groups with high and low numbers using median values as cutoff.
  • RESULTS: CD3+ and CD4+ TILs influenced no evidence of disease survival: 3-year rates for patients with low numbers were 89% and 95%, respectively, and 54% (P = 0.02) and 48%, (P = 0.01), respectively, in cases with high numbers.
  • Large numbers of tumor-infiltrating granzyme B+ cytotoxic cells had a significant negative prognostic effect (P = 0.008), whereas no effect was observed for Treg.
  • CONCLUSIONS: TILs were identified as negative prognostic indicators in anal squamous cell carcinomas with granzyme B+ cytotoxic cells showing highest effect on outcome.
  • This is possibly explained by the selection of therapy-resistant tumor cell clones.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lymphocytes, Tumor-Infiltrating / immunology. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Regulatory / immunology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740757.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


74. Zhang J, Martins CR, Fansler ZB, Roemer KL, Kincaid EA, Gustafson KS, Heitjan DF, Clark DP: DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma. Clin Cancer Res; 2005 Sep 15;11(18):6544-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma.
  • PURPOSE: Anal intraepithelial neoplasia is associated with human papillomavirus infection and may progress to invasive squamous cell carcinoma (SCC), which is increasing in immunocompromised patients.
  • We hypothesize that anal intraepithelial neoplasia is associated with abnormal DNA methylation and that detection of these events may be used to improve screening programs.
  • EXPERIMENTAL DESIGN: Seventy-six patients were identified who underwent anal cytology screening and subsequent biopsy at our institution between 1999 and 2004.
  • The specimens from these patients included 184 anal biopsies [normal, n = 57; low-grade squamous intraepithelial lesion (LSIL), n = 74; high-grade squamous intraepithelial lesion (HSIL), n = 41; and invasive SCC, n = 12] and 37 residual liquid-based anal cytology specimens (normal, n = 11; LSIL, n = 12; HSIL, n = 14).
  • CONCLUSIONS: Aberrant DNA methylation is a frequent event in anal HSIL and SCC.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. DNA Methylation
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenomatous Polyposis Coli Protein / genetics. Adult. Biopsy. Carrier Proteins. Cell Adhesion Molecules. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA-Binding Proteins / genetics. Humans. Immunoglobulins / genetics. Kruppel-Like Transcription Factors. Membrane Proteins / genetics. Neoplasm Invasiveness. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. O(6)-Methylguanine-DNA Methyltransferase / genetics. Polymerase Chain Reaction / methods. Protein-Serine-Threonine Kinases / genetics. Receptors, Retinoic Acid / genetics. Transcription Factors / genetics. Tumor Suppressor Protein p14ARF / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166431.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adenomatous Polyposis Coli Protein; 0 / CADM1 protein, human; 0 / Carrier Proteins; 0 / Cell Adhesion Molecules; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA-Binding Proteins; 0 / HIC1 protein, human; 0 / Immunoglobulins; 0 / Kruppel-Like Transcription Factors; 0 / MLH1 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


75. Berry JM, Palefsky JM, Jay N, Cheng SC, Darragh TM, Chin-Hong PV: Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum; 2009 Feb;52(2):239-47
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia.
  • PURPOSE: High-resolution anoscopy is colposcopy of the anus after applying 3 percent acetic acid.
  • High-resolution anoscopy with biopsy was used as the standard for detecting high-grade anal neoplasia and was compared to detection of high-grade anal neoplasia by anal cytology, human papillomavirus testing, or the combination.
  • A specimen was taken for anal cytology and human papillomavirus testing, followed by high-resolution anoscopy with biopsy of any lesions.
  • RESULTS: Ninety-one percent of HIV-positive and 57 percent of HIV-negative MSM had anal human papillomavirus infection.
  • In HIV-positive men the sensitivity of abnormal cytology to detect high-grade anal neoplasia was 87 percent, and in HIV-negative MSM it was 55 percent.
  • Among HIV-negative men, 9 of 20 cases of high-grade anal neoplasia would have been missed because cytology was negative, but the addition of human papillomavirus positivity increased sensitivity for the combination to 90 percent.
  • CONCLUSIONS: Sensitivity and specificity of anal cytology and human papillomavirus testing are different in HIV-positive and HIV-negative MSM for detecting high-grade anal neoplasia when patients have high-resolution anoscopy-guided biopsy of lesions.
  • High-resolution anoscopy is an effective tool for diagnosing high-grade anal neoplasia.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / diagnosis. Carcinoma in Situ / diagnosis. Endoscopy, Gastrointestinal. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis
  • [MeSH-minor] Adult. Aged. Anus Diseases / diagnosis. Anus Diseases / virology. Biopsy. Cytodiagnosis. HIV Seronegativity. HIV Seropositivity / complications. Homosexuality. Humans. Male. Middle Aged. Polymerase Chain Reaction. Precancerous Conditions / diagnosis. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19279418.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01-RR-00079; United States / NIAID NIH HHS / AI / K23 AI054157; United States / NIAID NIH HHS / AI / R01 CA/AI 88739; United States / NCI NIH HHS / CA / R01 CA54053; United States / NCRR NIH HHS / RR / UL1 RR024131-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Hauerstock D, Ennis RD, Grossbard M, Evans A: Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer. Clin Colorectal Cancer; 2010 Oct;9(4):238-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
  • PURPOSE: The purpose of this retrospective study is to determine the results and the toxicity of concurrent chemoradiation for squamous cell carcinoma of the anal canal in HIV-positive patients treated at a single institution.
  • PATIENTS AND METHODS: HIV-positive patients with squamous cell carcinoma of the canal treated at Continuum Cancer Centers-affiliated hospitals were identified from tumor registries.
  • We reviewed hospital and treatment charts to gather data relating to demographics, HIV status including cluster of differentiation 4 (CD4) count and viral load, tumor stage, radiation and chemotherapy treatment, toxicity and local control, and survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / complications. Radiotherapy, Conformal


77. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients. J Gastrointest Surg; 2007 Nov;11(11):1410-5; discussion 1415-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients.
  • Anal dysplasia (low-grade squamous intraepithelial lesions, LSIL; high-grade squamous intraepithelial lesions, HSIL) is a challenging disease for the surgeon.
  • We reviewed 42 patients that underwent high-resolution anoscopy (HRA)-targeted surgical therapy of anal dysplasia in the past 10 years.
  • Patients were followed up in the Anal Neoplasia Clinic with physical examination, cytology, HRA, and biopsy if indicated.
  • Patients with disease amenable to local therapy were treated with office-based HRA-directed therapies.
  • HSIL was present in 33, with four undergoing planned staged treatment due to circumferential disease.
  • HRA-targeted surgical therapy coupled with surveillance and re-treatment with office-based therapies offered an effective method in controlling anal dysplasia in the immunocompetent patient.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / surgery

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710507.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Donigan M, Norcross LS, Aversa J, Colon J, Smith J, Madero-Visbal R, Li S, McCollum N, Ferrara A, Gallagher JT, Baker CH: Novel murine model for colon cancer: non-operative trans-anal rectal injection. J Surg Res; 2009 Jun 15;154(2):299-303

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel murine model for colon cancer: non-operative trans-anal rectal injection.
  • Different magnifications (10x versus 100x) were used for injection, and primary tumor growth and metastatic disease were studied.
  • RESULTS: In the initial study, 3/7 mice injected using 10x magnifications had notable, large tumor originating from the rectal wall, and histology revealed that all excised tumors were poorly differentiated adenocarcinoma.
  • In the second study, 8/10 mice injected using 100x magnifications had notable tumor originating from the rectal well, and 4/8 mice had abnormal lung tissue with pathological evidence of hemorrhagic pulmonary edema.
  • The use of 10x magnification resulted in 43% tumor take.
  • In sharp contrast, 80% tumor take was observed with 100x magnification.
  • The overall success of tumor take was 65% using the trans-anal rectal injection model.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Disease Models, Animal. Mice, Inbred BALB C. Neoplasm Transplantation / methods. Rectum / pathology
  • [MeSH-minor] Anal Canal. Animals. Cell Differentiation. Cell Line, Tumor. Injections / methods. Lung / pathology. Lung Neoplasms / secondary. Mice. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101690.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Spugnini EP, Dotsinsky I, Mudrov N, Bufalini M, Giannini G, Citro G, Feroce F, Baldi A: Adjuvant electrochemotherapy for incompletely excised anal sac carcinoma in a dog. In Vivo; 2008 Jan-Feb;22(1):47-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant electrochemotherapy for incompletely excised anal sac carcinoma in a dog.
  • Canine anal sac gland carcinoma (ASGC) is a frequently described neoplasm that is highly aggressive and can frequently lead to metastatic spread.
  • In this paper, we describe the successful treatment of an incompletely excised ASGC by using cisplatin selectively driven within the tumor cells by trains of biphasic pulses.
  • [MeSH-major] Anal Gland Neoplasms / drug therapy. Anal Sacs / drug effects. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Dog Diseases / drug therapy. Electrochemotherapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Disease-Free Survival. Dogs. Male. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396781.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


80. Cotter SE, Grigsby PW, Siegel BA, Dehdashti F, Malyapa RS, Fleshman JW, Birnbaum EH, Wang X, Abbey E, Tan B, Kodner IJ, Hunt SR, Lowney JK, Mutch MG, Dietz DW, Myerson RJ: FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys; 2006 Jul 1;65(3):720-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT in the evaluation of anal carcinoma.
  • PURPOSE: Surgical staging and treatment of anal carcinoma has been replaced by noninvasive staging studies and combined modality therapy.
  • In this study, we compare computed tomography (CT) and physical examination to [(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the staging of carcinoma of the anal canal, with special emphasis on determination of spread to inguinal lymph nodes.
  • METHODS AND MATERIALS: Between July 2003 and July 2005, 41 consecutive patients with biopsy-proved anal carcinoma underwent a complete staging evaluation including physical examination, CT, and 2-FDG-PET/CT.
  • RESULTS: [(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) detected 91% of nonexcised primary tumors, whereas CT visualized 59%.
  • CONCLUSION: [(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography detects the primary tumor more often than CT.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16626889.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


81. Uronis HE, Bendell JC: Anal cancer: an overview. Oncologist; 2007 May;12(5):524-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: an overview.
  • Anal cancer is a rare tumor with an incidence that has been rising over the last 25 years.
  • The disease was once thought to develop as a result of chronic irritation, but it is now known that this is not the case.
  • HIV infection is also associated with anal cancer; there is a higher incidence in HIV-positive patients but the direct relationship between HIV and anal cancer has been difficult to separate from the prevalence of HPV in this population.
  • HIV infection is also associated with anal cancer; there are increasing numbers of HIV-positive patients being diagnosed with the disease.
  • Treatment of anal cancer prior to the 1970s involved abdominoperineal resection, but the standard of care is now concurrent chemoradiation therapy, with surgery reserved for those patients with residual disease.
  • We present a case of anal cancer followed by a general discussion of both risk factors and treatment.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adenocarcinoma / therapy. HIV Infections / complications. Humans. Male. Middle Aged. Neoplasm Staging. Papillomavirus Infections / complications. Risk Factors

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17522240.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


82. Spugnini EP, Filipponi M, Romani L, Dotsinsky I, Mudrov N, Baroni A, Ruocco E, Laieta MT, Montesarchio V, Cassandro R, Citro G, Baldi A: Local control and distant metastasis after electrochemotherapy of a canine anal melanoma. In Vivo; 2007 Sep-Oct;21(5):897-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local control and distant metastasis after electrochemotherapy of a canine anal melanoma.
  • Canine anal melanoma is an aggressive neoplasm that rapidly leads to constipation in dogs, thus mimicking the behavior of their human counterpart.
  • In this paper, the successful local palliation of this neoplasm is described using cisplatin selectively driven within the tumor cells by trains of biphasic pulses.
  • The dog experienced tumor reduction with restoration of normal defecation for three months, then experienced massive dissemination to the sublumbar lymph nodes that led to intestinal obstruction and euthanasia.
  • Electrochemotherapy (ECT) is a safe palliative therapy for such neoplasm and warrants further investigations in dogs as well humans.
  • [MeSH-major] Anus Neoplasms / veterinary. Dog Diseases / drug therapy. Dog Diseases / pathology. Electrochemotherapy. Melanoma / veterinary
  • [MeSH-minor] Animals. Dogs. Female. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019432.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


83. Chapet O, Gerard JP, Riche B, Alessio A, Mornex F, Romestaing P: Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys; 2005 Dec 1;63(5):1316-24
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer.
  • PURPOSE: To evaluate whether the tumor response after an initial course of irradiation predicts for colostomy-free survival and overall survival in patients with anal canal cancer.
  • An evaluation of tumor regression, before the boost, was available for 221 patients.
  • They were divided into four groups according to the tumor response: <70%, 70-80%, >80% but <100%, and 100%.
  • The disease-free survival rate was 60.0% +/- 3.3% and 49.4% +/- 3.9% at 5 and 10 years, respectively.
  • Two groups could be differentiated according to the percentage of tumor regression before the boost: >80% vs. < or = 80%.
  • The group with a T3-T4 lesion and tumor regression < or = 80% had the poorest overall (52.8% +/- 12.3%), disease-free (19.9% +/- 9.9%), and colostomy-free survival (24.8% +/- 11.2%) rates.
  • CONCLUSION: The amount of tumor regression before EBRT or brachytherapy boost is a strong prognostic factor of disease control without colostomy.
  • When regression is < or = 80% in patients with an initial T3-T4 lesion, the use of conservative RT should be carefully evaluated because of the very poor disease-free and colostomy-free survival.
  • [MeSH-major] Anus Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Brachytherapy. Colostomy. Disease-Free Survival. Female. Humans. Iridium Radioisotopes / therapeutic use. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169674.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


84. Allison RR, Sheng C, Cuenca R, Bagnato VS, Austerlitz C, Sibata CH: Photodynamic therapy for anal cancer. Photodiagnosis Photodyn Ther; 2010 Jun;7(2):115-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for anal cancer.
  • Invasive anal cancers are generally successfully treated by combined chemotherapy with radiation therapy (XRT).
  • We examined the treatment and outcome of Photofrin based photodynamic therapy (PDT) in a cohort of patients with anal cancer who failed locally despite chemo-radiation (N=6) and two patients with positive margins of resection after excision of small T(1) squamous cell anal cancers who refused further surgery or chemo-radiation.
  • Red light (630 nm) illumination was delivered by a 5 cm diffusing fiber, treating transphincterally at 300 J/cm followed by microlens illumination at 200 J/cm(2) to the perianal tumor bed with 2 cm margin.
  • All patients completed PDT without incident and all have maintained local control of disease in the anal region for the length of follow up (18-48 months).
  • PDT may serve as a new means to salvage local failures and perhaps could be employed as a primary treatment modality in select patients with early stage of disease.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Dihematoporphyrin Ether / therapeutic use. Photochemotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20510306.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  • [Number-of-references] 22
  •  go-up   go-down


85. Yokoyama Y, Nishimura Y, Yatsuoka T, Sakamoto H, Tanaka Y, Nishimura Y, Kurosumi M: [A case of anal metastasis from sigmoid colon cancer in a long-term survivor who had repeated local excisions]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2585-7
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of anal metastasis from sigmoid colon cancer in a long-term survivor who had repeated local excisions].
  • In March 2001, he complained of an anal bleeding and underwent colonoscopy.
  • It showed a submucosal tumor 15 mm in diameter at the anal canal and the biopsy indicated a moderately differentiated adenocarcinoma.
  • This tumor was suspected of metastasis from sigmoid colon cancer and transanal resection was performed in May 2001.
  • The diagnosis of anal metastasis was made on the basis of three points.
  • First, tumor was covered with anal epithelium.
  • Thirdly, there were no findings of other primary anal cancer.
  • By removing anal canal metastases twice, inguinal lymph node metastases three times and lung metastases in each time, he survived for 11 years after a primary surgery.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Anus Neoplasms / secondary. Anus Neoplasms / surgery. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224647.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


86. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • Neoadjuvant radiotherapy was given in 12 patients (24 percent) who had preoperative endoanal ultrasound findings of tumor extension beyond the muscularis propria and chemoradiotherapy in 7 (14 percent) of these patients where the tumor was more bulky and fixed.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • The ileostomy had been closed in 50 patients, and at last follow-up, the median stool frequency was two (1-8) bowel movements per day.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


87. Lewis-Tuffin LJ, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, Anastasiadis PZ: Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One; 2010 Oct 27;5(10):e13665
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype.
  • Cadherin switching is also common during epithelial tumor progression, where it is thought to promote tumor invasion and metastasis.
  • CONCLUSIONS/SIGNIFICANCE: Our data shows an unexpected correlation between the abnormal expression of E-cadherin in a subset of GBM tumor cells and the growth and migration of this aggressive brain tumor subtype.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1997 Dec;183(4):404-11 [9496256.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1167-74 [17363510.001]
  • [Cites] In Vivo. 1998 Jul-Aug;12(4):369-74 [9706486.001]
  • [Cites] Anal Biochem. 1999 Feb 1;267(1):217-21 [9918674.001]
  • [Cites] Trends Biochem Sci. 1999 Feb;24(2):73-6 [10098402.001]
  • [Cites] Curr Opin Cell Biol. 1999 Oct;11(5):554-60 [10508659.001]
  • [Cites] Curr Opin Cell Biol. 1999 Oct;11(5):561-6 [10508653.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):3-15 [15527101.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):164-76 [15831234.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):622-34 [16025097.001]
  • [Cites] Mol Endocrinol. 2005 Oct;19(10):2564-78 [15928314.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Cell Biol. 2007 Jul 30;178(3):517-27 [17646397.001]
  • [Cites] J Biol Chem. 2008 Feb 22;283(8):5014-22 [18089563.001]
  • [Cites] J Cell Sci. 2008 Mar 15;121(Pt 6):727-35 [18322269.001]
  • [Cites] BMC Genomics. 2008;9:54 [18230158.001]
  • [Cites] Dev Growth Differ. 2008 Jun;50 Suppl 1:S119-30 [18430170.001]
  • [Cites] Genet Mol Res. 2008;7(2):295-304 [18551395.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3993-4001 [18559622.001]
  • [Cites] Cancer. 2008 Nov 15;113(10):2779-89 [18816605.001]
  • [Cites] J Cell Biol. 2008 Nov 17;183(4):737-49 [19015320.001]
  • [Cites] Neoplasia. 2009 Apr;11(4):377-87 [19308292.001]
  • [Cites] J Neurosci. 2009 Mar 25;29(12):3885-96 [19321785.001]
  • [Cites] J Neurooncol. 2010 Apr;97(2):225-32 [19806322.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):399-404 [10662767.001]
  • [Cites] Prog Neurobiol. 2000 Aug;61(6):611-48 [10775799.001]
  • [Cites] Neurosurg Rev. 2000 Mar;23(1):39-44 [10809486.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):992-1005 [10931041.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2000 Jul 29;355(1399):885-90 [11128982.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Lett. 2002 Sep 8;183(1):95-101 [12049819.001]
  • [Cites] J Neurooncol. 2002 May;57(3):187-92 [12125981.001]
  • [Cites] J Cell Sci. 2002 Aug 15;115(Pt 16):3331-40 [12140264.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1624-36 [12697889.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] Mol Cell Endocrinol. 2003 Apr 28;202(1-2):89-96 [12770736.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):749-55 [14506634.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jan;39(1):29-36 [14603439.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2327-32 [14676814.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):118-32 [14964308.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):739-45 [15148503.001]
  • [Cites] Clin Neuropathol. 2004 Jul-Aug;23(4):141-8 [15328877.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1981-7 [1551127.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):806-11 [8240824.001]
  • [Cites] Mod Pathol. 1994 Sep;7(7):752-61 [7824509.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):627-33 [7669572.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2264-71 [16609043.001]
  • [Cites] J Cell Biol. 2006 Sep 25;174(7):1087-96 [16982802.001]
  • [Cites] Neurosurg Focus. 2006;21(4):E13 [17112191.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1773(1):34-46 [17028013.001]
  • [Cites] Nat Rev Neurosci. 2007 Jan;8(1):11-20 [17133224.001]
  • [Cites] Brain Tumor Pathol. 1997;14(1):27-33 [9384799.001]
  • (PMID = 21060868.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R21 NS070117; United States / NCI NIH HHS / CA / P50 CA108961; United States / NINDS NIH HHS / NS / T32 NS007494; United States / NCI NIH HHS / CA / R01 CA100467; United States / NINDS NIH HHS / NS / R01 NS069753; United States / NINDS NIH HHS / NS / T32NS07494
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins
  • [Other-IDs] NLM/ PMC2965143
  •  go-up   go-down


88. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med; 2010 Mar 11;362(10):875-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.
  • BACKGROUND: Despite advances in treatments for Hodgkin's lymphoma, about 20% of patients still die from progressive disease.
  • RESULTS: Gene-expression profiling identified a gene signature of tumor-associated macrophages that was significantly associated with primary treatment failure (P=0.02).
  • In an independent cohort of patients, we found that an increased number of CD68+ macrophages was correlated with a shortened progression-free survival (P=0.03) and with an increased likelihood of relapse after autologous hematopoietic stem-cell transplantation (P=0.008), resulting in shortened disease-specific survival (P=0.003).
  • In multivariate analysis, this adverse prognostic factor outperformed the International Prognostic Score for disease-specific survival (P=0.003 vs. P=0.03).
  • The absence of an elevated number of CD68+ cells in patients with limited-stage disease defined a subgroup of patients with a long-term disease-specific survival of 100% with the use of current treatment strategies.
  • CONCLUSIONS: An increased number of tumor-associated macrophages was strongly associated with shortened survival in patients with classic Hodgkin's lymphoma and provides a new biomarker for risk stratification.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Massachusetts Medical Society
  • [Cites] Ann Oncol. 2006 Jan;17(1):110-6 [16291580.001]
  • [Cites] Immunol Rev. 2006 Apr;210:67-85 [16623765.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Blood. 2006 Jul 15;108(2):662-8 [16551964.001]
  • [Cites] Bone Marrow Transplant. 2007 Jan;39(1):41-7 [17115062.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3101-8 [17536082.001]
  • [Cites] J Surg Res. 2007 Sep;142(1):119-28 [17597158.001]
  • [Cites] Eur J Haematol. 2007 Nov;79(5):455-61 [17908180.001]
  • [Cites] Am J Clin Pathol. 2007 Dec;128(6):958-65 [18024321.001]
  • [Cites] Haematologica. 2008 Feb;93(2):193-200 [18223287.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1759-66 [18347177.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2765-3775 [19096012.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5920-6 [19188663.001]
  • [Cites] Oncogene. 2002 May 2;21(19):3095-102 [12082542.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):310-4 [12872350.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:225-47 [14633784.001]
  • [Cites] J Nutr. 2004 Apr;134(4):762-70 [15051823.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7 [15075390.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1478-84 [1383821.001]
  • [Cites] Ann Oncol. 1995 Nov;6(9):895-9 [8624292.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1467-73 [15746048.001]
  • [Cites] Blood. 2005 May 15;105(10):3979-86 [15677569.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3773-9 [15809450.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2005 Jun;27(6):957-68 [15943426.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Cell Immunol. 2005 May;235(1):21-8 [16165118.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1581-91 [16236613.001]
  • [CommentIn] N Engl J Med. 2010 Mar 11;362(10):942-3 [20220189.001]
  • [CommentIn] N Engl J Med. 2010 Jun 3;362(22):2135; author reply 2136 [20527079.001]
  • [CommentIn] N Engl J Med. 2010 Jun 3;362(22):2135-6; author reply 2136 [20527059.001]
  • [CommentIn] N Engl J Med. 2010 Jun 3;362(22):2135; author reply 2136 [20519687.001]
  • (PMID = 20220182.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; Canada / Canadian Institutes of Health Research / / 178536; United States / NCI NIH HHS / CA / U01 CA114778-05; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / U01-CA114778-01; United States / NCI NIH HHS / CA / CA114778-05; United States / NCI NIH HHS / CA / U01-CA 114778
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS194035; NLM/ PMC2897174
  •  go-up   go-down


89. Zhang JY, Looi KS, Tan EM: Identification of tumor-associated antigens as diagnostic and predictive biomarkers in cancer. Methods Mol Biol; 2009;520:1-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of tumor-associated antigens as diagnostic and predictive biomarkers in cancer.
  • Many studies demonstrated that cancer sera contain antibodies which react with autologous cellular antigens generally known as tumor-associated antigens (TAAs).
  • With these two techniques, we identify sera which have high-titer fluorescent staining or strong signals to cell extracts on Western blotting and subsequently use these sera as probes in immunoscreening cDNA expression libraries, and also in proteomic approaches to isolate and identify targeted antigens which might potentially be involved in malignant transformation.
  • In extension of these studies, we evaluate the sensitivity and specificity of different antigen-antibody systems as markers in cancer in order to develop "tumor-associated antigen array" systems for cancer diagnosis, cancer prediction, and for following the response of patients to treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1777-88 [10766157.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1123-33 [16083262.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):945-53 [11549587.001]
  • [Cites] J Clin Invest. 2001 Nov;108(10):1411-5 [11714730.001]
  • [Cites] Mol Cell Proteomics. 2002 Mar;1(3):197-203 [12096119.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):5006-15 [12118381.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):136-43 [12582023.001]
  • [Cites] Technol Cancer Res Treat. 2002 Aug;1(4):257-62 [12625784.001]
  • [Cites] Int J Cancer. 1982 Oct 15;30(4):403-8 [6292117.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Apr;82(7):2115-9 [3856888.001]
  • [Cites] Cancer Res. 1992 Aug 1;52(15):4168-74 [1322237.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):26-35 [8380118.001]
  • [Cites] J Clin Invest. 1993 Nov;92(5):2419-26 [8227358.001]
  • [Cites] J Cell Sci. 1993 Dec;106 ( Pt 4):1045-56 [7907337.001]
  • [Cites] Exp Cell Res. 1994 Jun;212(2):255-61 [7910562.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3363-7 [9363867.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1163-7 [9547328.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1349-54 [9547346.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):5-7 [9874760.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • [Cites] Prostate. 2005 Jan 1;62(1):14-26 [15389814.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2756-9 [10850408.001]
  • (PMID = 19381943.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA056956; United States / NIGMS NIH HHS / GM / 2S06GM008012-37; United States / NCRR NIH HHS / RR / 5G12RR08124; United States / NIGMS NIH HHS / GM / S06 GM008012-390010; United States / NCRR NIH HHS / RR / G12 RR008124; United States / NIGMS NIH HHS / GM / S06 GM008012; United States / NCI NIH HHS / CA / CA56956; United States / NIGMS NIH HHS / GM / GM008012-390010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS183653; NLM/ PMC2839120
  •  go-up   go-down


90. von Roon AC, Tekkis PP, Clark SK, Heriot AG, Lovegrove RE, Truvolo S, Nicholls RJ, Phillips RK: The impact of technical factors on outcome of restorative proctocolectomy for familial adenomatous polyposis. Dis Colon Rectum; 2007 Jul;50(7):952-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary outcomes were major complications, pouch function, and neoplastic transformation in the anal transitional zone.
  • The incidence of polyps at the anal transitional zone was lower with handsewn than with stapled anastomosis (19 vs. 38 percent; P=0.047).
  • Handsewn ileoanal anastomosis with mucosectomy seems to reduce the incidence of subsequent neoplasia in the anal transitional zone but does not eliminate the risk of cancer.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Incidence. Length of Stay. Male. Neoplasm Recurrence, Local / epidemiology. Postoperative Complications / epidemiology. Retrospective Studies. Risk Factors. Time Factors. Treatment Outcome


91. Klenova A, Balabanova A: [Conservative treatment of the spinocellular cancer of the anal canal--a brief survey and report on 6 cases]. Khirurgiia (Sofiia); 2008;(3):25-31
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Conservative treatment of the spinocellular cancer of the anal canal--a brief survey and report on 6 cases].
  • PURPOSE: The conservative treatment for carcinoma of the anal canal has become the standard care for this malignancy.
  • MATERIAL AND METHODS: Between February and December 2003 six female patients with UICC T2-3, No, Mo, G1-G2 squamous-cell carcinoma of the anal canal were treated.
  • The disease was proved with digital examination, biopsy, endorectal ultrasound and spiral CT scan.
  • The total tumor dose of 50.4 Gy, 1.8 Gy/day, 5 fractions weekly, was delivered to the pelvis and the primary tumor; for the inguinal lymph nodes the total dose was 41.4 Gy, 1.8 Gy/day, 5 fractions weekly.
  • After interruption of 14 days, a local boost irradiation to the primary tumor was given--16 Gy, 2 Gy/day, 5 fractions weekly.
  • Complete tumor regression was obtained in all treated cases.
  • With a median follow-up of 48 months all six patients are still alive, without signs of disease.
  • The therapy was well tolerated, with good anal continence and moderate late side effects, including soft chronic diarrhea.
  • [MeSH-major] Anal Canal / pathology. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / radiography

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063470.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


92. Ishiyama S, Inoue S, Kobayashi K, Sano Y, Kushida N, Yamazaki Y, Yanaga K: Implantation of rectal cancer in an anal fistula: report of a case. Surg Today; 2006;36(8):747-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implantation of rectal cancer in an anal fistula: report of a case.
  • A 53-year-old man who had had an anal fistula for 20 years was admitted to our hospital with a large intestinal obstruction.
  • Barium enema and colonoscopy confirmed advanced rectal cancer and we palpated a soft tumor, 3 cm in diameter, with inflammatory induration on the right side of the rectum.
  • After draining a perianal abscess caused by the anal fistula, we performed low anterior resection.
  • Histological examination of the perianal necrotic tissue obtained during resection of the perianal tumor encompassing the anal fistula revealed adenocarcinoma.
  • Since the histology of the perianal lesion was identical to that of the rectal cancer, a diagnosis of cancer implantation rather than carcinoma originating in the anal fistula was entertained.
  • Although the recurrence of rectal cancer by mucosal implantation is not uncommon, the coincidental implantation of rectal cancer in an anal fistula is extremely rare.
  • [MeSH-major] Adenocarcinoma / pathology. Anus Neoplasms / pathology. Neoplasm Seeding. Rectal Fistula / complications. Rectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1955 Jul-Aug;8(4):831-8 [13240668.001]
  • [Cites] Dis Colon Rectum. 2003 Jun;46(6):835-6 [12794588.001]
  • [Cites] Acta Chir Belg. 2002 Jun;102(3):212-3 [12136546.001]
  • [Cites] Aust N Z J Surg. 1965 Feb;34:178-87 [14271060.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):602 [4027530.001]
  • [Cites] Surgery. 1954 Jul;36(1):136-9 [13178955.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):664-5 [6478153.001]
  • [Cites] J R Soc Med. 1992 Jun;85(6):361 [1625275.001]
  • [Cites] Surg Today. 2001;31(12):1094-6 [11827191.001]
  • (PMID = 16865523.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


93. Provencher S, Oehler C, Lavertu S, Jolicoeur M, Fortin B, Donath D: Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. Radiat Oncol; 2010;5:41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma.
  • PURPOSE: To evaluate quality of life (QOL) and outcome of patients with anal carcinoma treated with short split-course chemoradiation (CRT).
  • METHODS: From 1991 to 2005, 58 patients with anal cancer were curatively treated with CRT.
  • Significant anal pain or fecal incontinence was infrequently reported.
  • CONCLUSIONS: Short split-course CRT for anal carcinoma seems to be associated with good local control, survival and long-term global QOL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Quality of Life. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1274-83 [12873671.001]
  • [Cites] Brachytherapy. 2007 Jul-Sep;6(3):218-26 [17681244.001]
  • [Cites] Br J Surg. 1985 Apr;72(4):282-5 [3986477.001]
  • [Cites] Cancer. 1991 May 15;67(10):2462-6 [2015547.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):441-50 [9559628.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1588-94 [10408404.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Dec;16(8):530-5 [15630846.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] Radiother Oncol. 2007 Aug;84(2):107-13 [17707936.001]
  • [Cites] Radiother Oncol. 1999 Sep;52(3):239-43 [10580870.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):669-78 [12573754.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(2):189-93 [17189954.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(10):1564-73 [17521904.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • (PMID = 20492729.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2883545
  •  go-up   go-down


94. Khanfir K, Ozsahin M, Bieri S, Cavuto C, Mirimanoff RO, Zouhair A: Patterns of failure and outcome in patients with carcinoma of the anal margin. Ann Surg Oncol; 2008 Apr;15(4):1092-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure and outcome in patients with carcinoma of the anal margin.
  • BACKGROUND: To evaluate the outcome of patients with carcinoma of anal margin in terms of recurrence, survival, and radiation toxicity.
  • METHODS: A series of 45 consecutive patients, with anal margin carcinoma treated between 1983 and 2006 with curative intent at two institutions, was retrospectively analyzed.
  • The 5-year disease-specific survival (DSS) and overall survival (OS) rates were respectively 86% (95% CI, 72-99%) and 55% (95% CI, 44-66%).
  • The overall anal conservation rate was 80% for the whole series.
  • There was no significant association between local recurrence and patient age, histological grade, tumor size, T stage, overall treatment time, RT dose, or chemotherapy.
  • CONCLUSIONS: We conclude that definitive RT and/or BT yield a good local control and disease-specific survival comparable with published data.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231838.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Bean SM, Eltoum I, Horton DK, Whitlow L, Chhieng DC: Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia. Am J Surg Pathol; 2007 Apr;31(4):555-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia.
  • Anal intraepithelial neoplasia (AIN) is a human papilloma virus related lesion.
  • The objective of this study is to correlate p16 expression and cellular proliferation measured by Ki-67 staining with the degree of dysplasia in the anal canal and to determine the efficacy of these markers in diagnosing high-grade AIN.
  • Seventy-five anal specimens from 55 patients (37 men; 18 women; mean age: 48 y; median: 44 y; range 25 to 96 y) were studied including 35 normal/reactive lesions, 23 low-grade AIN (AIN I and condyloma), and 17 high-grade AIN (AIN II and III).
  • [MeSH-major] Anus Neoplasms / diagnosis. Genes, p16. Ki-67 Antigen / metabolism. Papillomavirus Infections / diagnosis. Precancerous Conditions / diagnosis. Tumor Virus Infections / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / virology. Female. History, 17th Century. Humans. Immunohistochemistry. Male. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414102.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


96. Duensing A, Chin A, Wang L, Kuan SF, Duensing S: Analysis of centrosome overduplication in correlation to cell division errors in high-risk human papillomavirus (HPV)-associated anal neoplasms. Virology; 2008 Mar 1;372(1):157-64
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of centrosome overduplication in correlation to cell division errors in high-risk human papillomavirus (HPV)-associated anal neoplasms.
  • High-risk HPV-associated anal neoplasms are difficult to treat and biomarkers of malignant progression are needed.
  • However, a detailed analysis of centrosome overduplication in primary HPV-associated neoplasms has not been performed so far.
  • Here, we determined the frequency of centrosome overduplication in HPV-associated anal lesions using a recently identified marker for mature maternal centrioles, Cep170.
  • Remarkably, centrosome overduplication, but not aberrant centrosome numbers per se or centrosome accumulation, correlated significantly with the presence of cell division errors.
  • In addition, our experiments revealed that in particular pseudo-bipolar mitoses may play a role in the propagation of chromosomal instability in high-risk HPV-associated tumors.
  • These results provide new insights into the role of centrosome aberrations in cell division errors and encourage further studies on centrosome overduplication as a predictive biomarker of malignant progression in HPV-associated anal lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol Res Commun. 1999 Sep-Dec;2(3):190-6 [10662596.001]
  • [Cites] Adv Dent Res. 2006;19(1):99-105 [16672559.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2356-60 [11289095.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):279-84 [11301343.001]
  • [Cites] Biochim Biophys Acta. 2001;1471(2):M81-8 [11342187.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] Inflamm Res. 2002 Aug;51(8):416-22 [12234059.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):815-25 [12415252.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7075-82 [12460929.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]
  • [Cites] Microbiol Mol Biol Rev. 2004 Jun;68(2):362-72 [15187189.001]
  • [Cites] Mol Cancer. 2003 Sep 8;2:30 [14498992.001]
  • [Cites] N Engl J Med. 1984 Apr 5;310(14):880-3 [6321986.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Curr Opin Oncol. 1995 Sep;7(5):437-41 [8541389.001]
  • [Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]
  • [Cites] Acta Oncol. 1997;36(1):3-12 [9090961.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Jun;104(6):723-7 [9197877.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Aug;19(4):233-40 [9258658.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4210-3 [9331077.001]
  • [Cites] Cancer Lett. 1998 Jan 16;123(1):47-52 [9461017.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2950-5 [9501196.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):15-20 [9709296.001]
  • [Cites] Mol Biol Cell. 2005 Mar;16(3):1095-107 [15616186.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):277-90 [15736144.001]
  • [Cites] Cell Biol Int. 2005 May;29(5):352-9 [15890539.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):182-9 [16186736.001]
  • [Cites] Nature. 2005 Oct 13;437(7061):1043-7 [16222300.001]
  • [Cites] Curr Opin Cell Biol. 2006 Feb;18(1):74-8 [16361091.001]
  • [Cites] Cell Cycle. 2006 Dec;5(24):2899-902 [17172866.001]
  • [Cites] Int J STD AIDS. 2007 Feb;18(2):77-80 [17331275.001]
  • [Cites] Trends Cell Biol. 2007 May;17(5):215-21 [17383880.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):451-63 [17505520.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6280-8 [17438528.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10002-7 [10944189.001]
  • (PMID = 18036631.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112598-03; United States / NCI NIH HHS / CA / R01 CA112598; United States / NCI NIH HHS / CA / R01 CA 112598; United States / NCI NIH HHS / CA / R01 CA112598-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cep170 protein, human; 0 / Phosphoproteins; 0 / Tubulin
  • [Other-IDs] NLM/ NIHMS38243; NLM/ PMC2267749
  •  go-up   go-down


97. Huang K, Haas-Kogan D, Weinberg V, Krieg R: Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol; 2007 Feb 14;13(6):895-900
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal.
  • AIM: To assess whether radiation dose and duration of treatment influence local control and survival of patients with locally advanced anal cancer treated with definitive chemoradiation.
  • METHODS: Twenty-eight consecutive patients who were treated with definitive radiation therapy for bulky anal cancers (> 5 cm in size) were reviewed.
  • The median tumor size was 7.5 cm.
  • CONCLUSION: Local failure is a significant problem in locally advanced carcinomas of the anal canal.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):354-61 [16168830.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):823-31 [12788191.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1153-60 [2599903.001]
  • [Cites] Radiother Oncol. 1993 Jun;27(3):209-15 [8210457.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):745-9 [8690640.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):313-24 [9069302.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2329-35 [9191520.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):249-56 [9572617.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):525-32 [9778618.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] Cancer J Sci Am. 1996 Jul-Aug;2(4):205-11 [9166533.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • (PMID = 17352019.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4065925
  •  go-up   go-down


98. Santos AM, Jung J, Aziz N, Kissil JL, Puré E: Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest; 2009 Dec;119(12):3613-25
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice.
  • As the cell surface serine protease fibroblast activation protein (FAP) is selectively expressed on tumor-associated fibroblasts and pericytes in epithelial tumors, we set out to investigate the role of FAP in mouse models of epithelial-derived solid tumors.
  • In this study, we demonstrate that genetic deletion and pharmacologic inhibition of FAP inhibited tumor growth in both an endogenous mouse model of lung cancer driven by the K-rasG12D mutant and a mouse model of colon cancer, in which CT26 mouse colon cancer cells were transplanted into immune competent syngeneic mice.
  • Interestingly, growth of only the K-rasG12D-driven lung tumors was also attenuated by inhibition of the closely related protease dipeptidyl peptidase IV (DPPIV).
  • Our results indicate that FAP depletion inhibits tumor cell proliferation indirectly, increases accumulation of collagen, decreases myofibroblast content, and decreases blood vessel density in tumors.
  • These data provide proof of principle that targeting stromal cell-mediated modifications of the tumor microenvironment may be an effective approach to treating epithelial-derived solid tumors.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22482-91 [15805113.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):7595-601 [9065413.001]
  • [Cites] Bioorg Med Chem Lett. 2005 Oct 1;15(19):4239-42 [16085416.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14404-9 [16183744.001]
  • [Cites] FEBS Lett. 2006 Mar 6;580(6):1581-6 [16480718.001]
  • [Cites] J Biol Chem. 2006 Mar 17;281(11):7437-44 [16410248.001]
  • [Cites] Hum Pathol. 2006 Mar;37(3):352-60 [16613331.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(11):4201-13 [16705171.001]
  • [Cites] Arch Biochem Biophys. 2007 Jan 15;457(2):177-86 [17174263.001]
  • [Cites] BMC Med. 2006;4(1):38 [17190588.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1736-41 [17363526.001]
  • [Cites] Biochemistry. 2007 Apr 17;46(15):4598-605 [17381073.001]
  • [Cites] Genes Dev. 2007 Jul 15;21(14):1731-46 [17626791.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8089-94 [17804720.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):800-8 [17851543.001]
  • [Cites] Front Biosci. 2008;13:1634-45 [17981655.001]
  • [Cites] Front Biosci. 2008;13:3168-80 [17981786.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Biochemistry. 2008 Jan 22;47(3):1076-86 [18095711.001]
  • [Cites] Gastroenterology. 2008 Jun;134(7):1981-93 [18439605.001]
  • [Cites] Ultrastruct Pathol. 2008 May-Jun;32(3):89-96 [18570153.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4584-92 [18628473.001]
  • [Cites] Pancreas. 2008 Aug;37(2):154-8 [18665076.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] J Biol Chem. 2009 Feb 13;284(7):4647-57 [19047064.001]
  • [Cites] J Clin Pathol. 2009 Mar;62(3):236-49 [18930983.001]
  • [Cites] Biochem Pharmacol. 2005 Jul 1;70(1):134-43 [15907807.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36505-12 [10593948.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(3):1089-94 [10629066.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2602-6 [10825129.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):985-1000 [11891196.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4767-72 [12183436.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Oct;44(1):1-15 [12398996.001]
  • [Cites] J Invest Dermatol. 2003 Feb;120(2):182-8 [12542520.001]
  • [Cites] Onkologie. 2003 Feb;26(1):44-8 [12624517.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1639-47 [12738716.001]
  • [Cites] Hepatology. 1999 Jun;29(6):1768-78 [10347120.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7427-37 [15534120.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Mol Cancer Ther. 2005 Mar;4(3):351-60 [15767544.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19441-4 [15809306.001]
  • [Cites] J Med Chem. 2003 Jun 19;46(13):2774-89 [12801240.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):15-23 [12883993.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):375-87 [15093544.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5471-80 [15289357.001]
  • [Cites] Methods Biochem Anal. 1967;15:25-76 [4899619.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9 [2402505.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3327-35 [8391923.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1193-203 [8201382.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61 [7911242.001]
  • [Cites] Int J Cancer. 1994 Aug 1;58(3):385-92 [7519584.001]
  • [Cites] Eur J Cancer. 1994;30A(14):2170-80 [7857719.001]
  • [Cites] Genomics. 1995 Jan 1;25(1):335-7 [7774951.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):448-52 [9012803.001]
  • [CommentIn] Future Oncol. 2010 Mar;6(3):347-9 [20222791.001]
  • (PMID = 19920354.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA124495; United States / NCI NIH HHS / CA / T32 CA009171; United States / NCI NIH HHS / CA / T32 CA09171
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1-(((3-hydroxy-1-adamantyl)amino)acetyl)-2-cyanopyrrolidine; 0 / Membrane Proteins; 0 / Protease Inhibitors; 0 / Pyrrolidines; 9007-34-5 / Collagen; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases; PJY633525U / Adamantane
  • [Other-IDs] NLM/ PMC2786791
  •  go-up   go-down


99. Yang Y, Zhang L, Wei Y, Wang H, Xiong W, Chen Z, Hes O, Zheng J: Detection of EWSR1 translocation with nuclear extraction-based fluorescence in situ hybridization for diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor. Anal Quant Cytol Histol; 2007 Aug;29(4):221-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of EWSR1 translocation with nuclear extraction-based fluorescence in situ hybridization for diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor.
  • OBJECTIVE: To investigate nuclear extraction-based fluorescence in situ hybridization (NE-FISH) in EWSR1 translocation of Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) in formalin-fixed, paraffin-embedded (FFPE) tissue, compared to thin-section FISH (TS-FISH) and nested reverse-transcription polymerase chain reaction (RT-PCR).
  • STUDY DESIGN: Nuclei of the tumor cells and total ribonucleic acid (RNA) were extracted from 10 cases of ES/PNET.
  • NE-FISH and TS-FISH were used to analyze the EWS gene translocation.
  • RESULTS: Of 10 cases, 9 (90%) were abnormal by NE-FISH and TS-FISH.
  • The average rate of abnormal split signals detected by NE-FISH was significantly higher than by TS-FISH.
  • We analyzed 10 ES/PNET cases and 8 various normal human tissues by NE-FISH and nested RT-PCR.
  • Fusion signals were found in 9 (90%) ES/PNET cases by NE-FISH and 8 (80%) by nested RT-PCR.
  • CONCLUSION: NE-FISH is more reliable than TS-FISH in detecting EWSR1 translocation of ES/PNET in FFPE tissue, although the FISH techniques were concordant.
  • A combination of NE-FISH and nested RT-PCR would improve accuracy of molecular diagnosis of ES/PNET.

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879630.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calmodulin-Binding Proteins; 0 / DNA, Neoplasm; 0 / EWSR1 protein, human; 0 / RNA-Binding Proteins
  •  go-up   go-down


100. Lowe DB, Shearer MH, Jumper CA, Bright RK, Kennedy RC: Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases. J Virol; 2007 Feb;81(3):1313-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases.
  • Simian virus 40 (SV40) large tumor antigen (Tag) represents a virus-encoded tumor-specific antigen expressed in many types of human cancers and a potential immunologic target for antitumor responses.
  • By examining tumor protection in SV40 Tag-immunized wild-type BALB/c mice using an experimental pulmonary metastasis model, we attempted to address whether engagement of the immunoglobulin G Fc receptors (FcgammaRs) on effector cells is necessary to mediate antitumor responses.
  • However, all mice deficient in the activating FcgammaRI (CD64) and FcgammaRIII (CD16) were unable to mount protective immunologic responses against tumor challenge and developed tumor lung foci.
  • These results underscore the importance of effector cell populations expressing FcgammaRI/III within this murine tumor model system, and along with the production of a specific humoral immune response, antibody-dependent cell-mediated cytotoxicity (ADCC) may be a functioning mechanism of tumor clearance.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Rev Immunol. 2003 Mar-Apr;22(2):141-72 [12962273.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1040-5 [12615720.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5866-73 [14676108.001]
  • [Cites] J Exp Med. 2004 Jun 21;199(12):1659-69 [15210744.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4664-9 [15231679.001]
  • [Cites] Immunol Rev. 2004 Jun;199:54-67 [15233726.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5825-9 [15313926.001]
  • [Cites] Int J Cancer. 1969 Jul 15;4(4):384-92 [4310402.001]
  • [Cites] Virology. 1988 Nov;167(1):72-81 [3055666.001]
  • [Cites] J Immunol. 1989 Oct 1;143(7):2133-41 [2528589.001]
  • [Cites] J Immunol. 1990 Aug 1;145(3):932-9 [1695650.001]
  • [Cites] Cancer Immunol Immunother. 1993 Jul;37(1):31-9 [7685654.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5734-9 [7694794.001]
  • [Cites] Cell. 1994 Feb 11;76(3):519-29 [8313472.001]
  • [Cites] J Immunol. 1994 Sep 1;153(5):2064-71 [8051411.001]
  • [Cites] Nature. 1996 Jan 25;379(6563):346-9 [8552190.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1126-30 [8640771.001]
  • [Cites] J Immunol. 1996 Oct 15;157(8):3550-8 [8871655.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):652-6 [9435247.001]
  • [Cites] Anal Biochem. 1998 Feb 15;256(2):217-9 [9473280.001]
  • [Cites] J Virol Methods. 1997 Dec;69(1-2):93-102 [9504755.001]
  • [Cites] J Exp Med. 1999 Jan 4;189(1):187-94 [9874575.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 20;91(2):119-34 [9923853.001]
  • [Cites] Eur J Immunol. 1999 Jan;29(1):30-7 [9933083.001]
  • [Cites] Cancer Immunol Immunother. 1999 Feb;47(6):343-51 [10203065.001]
  • [Cites] Virology. 2005 Feb 5;332(1):28-37 [15661138.001]
  • [Cites] Science. 2005 Jan 28;307(5709):590-3 [15681388.001]
  • [Cites] Cancer Invest. 2005;23(5):413-9 [16193641.001]
  • [Cites] Immunity. 2005 Nov;23(5):503-14 [16286018.001]
  • [Cites] J Cell Biochem. 2006 May 15;98(2):235-42 [16440328.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):383-93 [16622476.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):343-57 [16622479.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • [Cites] J Immunol. 2000 Jun 15;164(12):6268-75 [10843680.001]
  • [Cites] Science. 2000 Oct 6;290(5489):84-9 [11021804.001]
  • [Cites] Annu Rev Immunol. 2001;19:275-90 [11244038.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):957-64 [12459734.001]
  • [Cites] Cell Immunol. 2003 Sep;225(1):21-32 [14643301.001]
  • (PMID = 17108042.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P40 RR012317; United States / NCRR NIH HHS / RR / RR-12317
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Receptors, IgG
  • [Other-IDs] NLM/ PMC1797535
  •  go-up   go-down






Advertisement